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FOREWORD

This dissertation has resulted to three publications.
Chapters III and IV which discuss the comparison of fruc
tose 6-phosphate-l-kinase (PFK) from Bacillus stearothermophilus and from E. coli, and the mutation at the fruc
tose 6-phosphate binding site have been combined into one
paper.

This has been accepted for publication in the

Journal of Biological Chemistry and is entitled "Sitedirected Mutagenesis in Bacillus stearothermophilus Fruc
tose 6-phosphate-l-kinase: Mutation at the Substrate Bind
ing Site Affects Allosteric Behavior" co-authored by B. C.
Valdez, B. A. French, E. S. Younathan and S. H. Chang.
The galley proof has been received and returned to the
publisher.

The paper is expected to appear in the journal

in January, 1989.
Mutation at the regulatory site (Chapter V) has been
published in Biochemical and Biophysical Research Communi
cation (Vol. 156, pp. 537-542) and is entitled "Sitedirected Mutagenesis at the Regulatory Site of Fructose 6phosphate-l-kinase from Bacillus stearothermophilus" co
authored by B. C. Valdez, S. H. Chang and E. S. Younathan.
The section on human muscle PFK gene (Chapter VI) has
been accepted for publication in Gene and is entitled
"Human 6-phosphofructo-l-kinase Gene Has an Additional
Intron Upstream of Initiation Codon".

iii

This is co-authored

by B. C. Valdez, Z. Chen, M. G. Sosa, E. S. Younathan and
S. H. Chang.

The revised manuscript has been submitted.
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ABSTRACT
Fructose 6-phosphate-l-kinase (PFK: EC. 2.7.1.11)
catalyzes the phosphorylation of
(Fru 6-P) to

g-fructose 6-phosphate

6-fructose 1,6-bisphosphate.

The first part

of this dissertation shows that PFK from Bacillus
stearothermophilus (BsPFK) unlike the major PFK from E .
coli (EcPFKA) exhibits a hyperbolic profile with respect
to Fru 6-P concentration in the absence of
phosphoenolpyruvate (PEP).

BsPFK is sensitive to

inhibition by high ATP concentrations and competitively
inhibited by GDP or ADP.
Arg-252 residue of BsPFK has been proposed to be
involved in the binding of Fru 6-P.

Mutation of this

residue to alanine (RA252) increases BsPFK affinity for
its inhibitor PEP (a 68-fold difference compared to wild
type) and dramatically decreases Fru 6-P affinity (1,500fold increase in Km).

Its higher sensitivity to ATP

inhibition is relieved by ADP, GDP or higher Fru 6-P
concentrations.

Mutation of Arg-252 to lysine (RK252)

increases the affinity of the enzyme for PEP by only 2fold and increases its Km for Fru 6-P by only 50-fold.
The data indicate that the Arg-252 residue plays a major
role in both Fru 6-P binding and allosteric interaction
between the subunits.
Arg-25, Arg-211 and Asp-59 residues have been mutated
to alanine; and Asp-59 also to methionine.

X

Arg-25 mutant

has half the affinity for Fru 6-P compared to the wild
type and exhibits sigmoidicity with respect to this
substrate (Hill # = 2.0).

Asp-59

Ala mutant has the

same affinity for PEP as the wild type whereas Asp 59
Met mutant has 3-fold higher affinity for this modulator
and the inhibition is reversed by GDP.

Arg-25 and Arg-211

mutants are 100-fold less sensitive to PEP inhibition
which is not relieved by GDP.

The data prove

unequivocally that Arg-25 and Arg-211, but not Asp-59, are
involved in the direct binding of PEP and GDP.
The last part of this dissertation involves isolation
of a clone containing the nontranslated 5' flanking region
of the human muscle PFK (HMPFK) gene.

It has an

additional intron extending from nucleotide -97 to -9
upstream of the ATG start codon.

Furthermore, HMPFK gene

is more AT rich than the rabbit gene.

CHAPTER I
INTRODUCTION

Background
Phosphofructokinase (PFK)

(ATP: g-D-fructose 6-

phosphate-l-phosphotransferase, E.C. 2.7.1.11) catalyzes
the transfer of the terminal phosphate from ATP to the Chydroxyl of g-D-fructose 6-phosphate (Fru 6-P) to produce
g-D-fructose 1,6-bisphosphate and ADP as shown below.
Fru 6-P2- + MgATP4"

*s=r Fru 1,6-P.,4' + MgADP3- + H+

This is the first committed step in glycolysis; hence it
is not surprising that this enzyme is subject to strong
regulation by various metabolites.

The extent of

regulation of this enzyme depends on its source.

In

general, bacterial PFKs are regulated by a smaller number
of modulators compared to PFKs from higher organisms.
Comprehensive reviews on PFK have been reported in the
literature (Bloxham and Lardy, 1973; Uyeda, 1979;
Younathan et_al., 1981).
Studies on the mechanism of action and the structure
function relationships of PFK are made possible by the
isolation of this enzyme in pure form from various
sources.

Most of the conclusions made are based on the

interpretation of kinetic data.

With the advances in

recombinant DNA technology the methodology to study these

relationships has become more sophisticated.

The first

part of this dissertation specifically involves studying
the structure-function relationships in PFK from Bacillus
stearothermophilus (BsPFK) by site-directed mutation.
Expression of eucaryotic genes is more complicated
than procaryotic genes.

A number of transcription factors

and cis-acting sequences are involved in eucaryotic gene
expression (Wingender, 1988).

The second part of this

dissertation involves cloning and sequencing the upstream
region of the human muscle fructose 6-phosphate-l-kinase
(HMPFK) gene.

This is an initial step to characterize the

promoter region of this gene and to identify any cisacting sequences probably involved in HMPFK gene
expression.

Reaction Mechanism of PFK
Phosphofructokinases differ in terms of kinetics of
their regulation.

This probably explains the various

reaction mechanisms of substrate-binding and productrelease reported in the literature for this enzyme.

Both

bi-bi sequential random and ping-pong mechanisms were
proposed for rabbit muscle PFK (Hanson et al., 1973;
Uyeda, 1970; Kee and Griffin, 1972; Bar-tana and Cleland,
1974).

An ordered sequencial mechanism was reported for

heart and liver PFKs (Hulme and Tipton, 1971; Brand and
Soling, 1974).

Studies on the reaction mechanism of procaryotic PFKs
are very limited.

Non-allosteric PFK from Lactobacillus

plantarum has been found to follow an ordered bi-bi
sequential mechanism where fructose 6-phosphate binds to
the enzyme first and ADP is the first product to be
released (Simon and Hofer, 1978).

The minor non-

allosteric PFK from E. coli (EcPFKB) follows the same
sequence of kinetic mechanism (Campos et al., 1984)
whereas the major allosteric PFK from E. coli (EcPFKA)
follows an opposite order of mechanism (i.e. ATP binds
first and Fru 1,6-P2 is the first product released)
(Kotlarz and Buc, 1981).

The determination of the order

of binding of substrates and release of products are based
on kinetic data.

This, however, does not provide

information about the exact bioorganic mechanism of
phosphoryl transfer.

Lowe et al. (1981) have used

isotopically labeled ATP to show the inversion of
configuration in the phosphoryl transfer catalyzed by PFK
from B. stearothermophilus and rabbit muscle.

This

implies an "in line" transfer of the phosphoryl group
between substrates in the Fru 6-P - Mg-ATP - enzyme
ternary complex.

Site-directed mutation has recently been

used to demonstrate that the same mechanism of phosphoryl
transfer holds true for EcPFKA (Hellinga and Evans, 1987).
In general, PFKs probably differ on the order of substrate
binding and release of products but they follow the same

bioorganic mechanism of phosphoryl transfer.

Regulation of PFK Activity
Procaryotic PFKs are half the molecular size _of
eucaryotic PFKs but their properties may be as diverse as
the mammalian enzyme.

Their allosteric behavior depends

on their sources and the requirement for metabolic
control.

Studies on the major E. coli PFK show sigmoidal

dependence of enzyme activity on the concentrations of the
substrate Fru 6-P (Atkinson and Walton, 1965; Blangy et
al., 1968).

Similar kinetic profile has been reported for

Lactobacillus acidophilus (Simon and Hofer, 1977),
Streptococcus lactis (Fordyce et al., 1982), Thermus X-l
(Cass and Steelwagen, 1975) and B. stearothermophilus
(Evans et al., 1981).

However, Valdez et al. (1988) show

that B. stearothermophilus exhibits a hyperbolic kinetic
profile with respect to Fru 6-P concentration similar to
PFKs from Lactobacillus plantarum (Simon and Hofer, 1977),
Streptococcus thermophilus (Simon and Hofer, 1981),
Bacillus licheniformis (Marschke and Bernlohr, 1982),
Flavobacterium thermophilus (Yoshida, 1978) and the minor
PFK from E. coli (Babul, 1978; Kotlarz and Buc, 1981).
At low Fru 6-P concentrations, ATP has been observed
to inhibit some bacterial PFKs (Simon and Hofer, 1977;
Fordyce et al., 1982; Marschke and Bernlohr, 1982; Babul,
1978; Kotlarz and Buc, 1981).

Phosphoenolpyruvate is a

common inhibitor among procaryotic PFKs.

The enzyme

isolated from L. acidophilus (Simon and Hofer, 1977) and
the minor E. coli PFK (Babul, 1978) are examples of
procaryotic PFKs insensitive to phosphoenolpyruvate.

In

general, an increase in the ADP concentration in bacterial
cells activates PFK, increasing the rate of glycolysis to
produce more ATP.

Accumulation of phosphoenolpyruvate

inhibits PFK in a feedback mechanism.
A thorough kinetic study made by Blangy et a l . (1968)
on EcPFKA shows that the properties of the enzyme may be
explained by the concerted transition theory proposed by
Monod et al. (1965).

The enzyme belongs to the K-system

where the R (relaxed) conformation has a higher binding
affinity for Fru 6-P and ADP than the T (tight)
conformation but both states have the same maximal
velocity.
PFKs from higher organisms are affected by numerous
metabolites.

This is explained by the vital role

glycolysis plays in carbohydrate metabolism.

This

regulation is made more complicated by the presence of
three PFK isozymes in animals (M-type, L-type and C-type
for muscle, liver and brain respectively).

In general,

eucaryotic PFKs are inhibited allosterically by high ATP
concentrations and it decreases the affinity for the
second substrate, Fru 6-P (Lardy and Parks, 1956; Hofmann,
1976; Uyeda, 1979).

This inhibition is relieved by the

degradation products of ATP (AMP, ADP and Pi)

(Passonneau

and Lowry, 1963; Tornheim and Lowenstein, 1976).

The

dependence of PFK activity on the ratio between ATP and
ADP or AMP concentration implies the importance of
regulation of this enzyme by the energy charge of a cell.
The link between glycolysis and TCA cycle is shown by
the inhibition of PFK by citrate in the presence of
inhibitory concentrations of ATP (Garland et al., 1963;
Passonneau and Lowry, 1963; Tsai and Kemp, 1974) .

Muscle

PFK is more sensitive to the inhibition when compared to
the brain or liver enzyme (Tsai and Kemp, 1974) which
implies isozyme differences in the sensitivity to citrate
inhibition.
Other effective inhibitors of eucaryotic PFKs are
phosphocreatine, 3-phosphoglycerate, 2-phosphoglycerate,
2,3-bisphosphoglycerate, 6-phosphogluconate and
phosphoenolpyruvate

(Bloxham and Lardy, 1973; Uyeda,

1979) .
The inhibition of eucaryotic PFKs may be relieved by
AMP, cAMP, ADP, Pi, Fru 6-P and Fru 1,6-P2 (Uyeda, 1979).
Other positive effectors include ammonium ion (Abrahams
and Younathan, 1971), Fru 2,6-P2 (Claus et al., 1981;
Kelley et al., 1986) Glu 1,6-P2 (Krzanowski and
Matshinsky, 1969), and Man 1,6-P2 (Rose and Warms, 1974).
Most eucaryotic PFKs exhibit cooperative Fru 6-P
binding.

Negative effectors shift the Fru 6-P saturation

curve to more sigmoidal form (decreases the apparent
affinity of Fru 6-P) while its positive effectors change
the curve to hyperbolic form (increases the affinity of
Fru 6-P).
It is interesting to consider, at this point, the
anomeric specificity of phosphofructokinase.
al.

Younathan et

(1981) have shown that rabbit muscle PFK is specific

for the

6-enantiomeric form of Fru 6-P.

On the other

hand, fructose 1,6-bisphosphatase, an important enzyme in
gluconeogenesis shows a preference for
(Benkovic et al., 1974).

a-Fru 1,6-P2

This shows the difference in the

specificity of the two enzymes involved in the Fru 6-P:
Fru 1,6-P2 futile cycle.
The physiological activities of some mammalian PFK's
are under hormonal regulation.

Insulin causes an increase

in liver and muscle PFK activity while glucagon has an
opposite effect (Taunton et al., 1972; Taunton et al.,
1974; Bauer and Younathan, 1984).

Early studies show that

the hormones probably affect the direct phosphorylation of
PFK (Nakatsu and Mansour, 1974; Brand and Soling, 1975).
However, the discovery of Fru 2,6-P2 gives a breakthrough
in the understanding of this stringent control.

Fru 2,6-

P2 is a potent activator of PFK and the level of this
metabolite is determined by the balance of flux of 6phosphofructo-2-kinase (PFK-2) and Fru 2,6-bisphosphatase
(FBPase-2), both located on the same polypeptide chain

(El-Magharabi et al., 1982: Tauler et al., 1988).
Phosphorylation of this bi-functional enzyme by cAMPdependent protein kinase activates the FBPase-2 and
inhibits the PFK-2 activities (Pilkis et al., 1987).
In addition to this post-translational regulation,
insulin probably enhances gene expression of the liver
isozyme.

Gehnrich et al. (1988) have shown that the level

of mouse liver PFK mRNA is under hormonal, dietary and
developmental control which is similar to what has been
observed for other hepatic glycolytic enzymes.

Immunological Cross-reactivity of PFKs
Immunological study is a technique that provides
structural and evolutionary relationships among proteins.
Immunological cross-reactivity among different enzymes
suggests the existence of similarity in their amino acid
sequence and spatial arrangement of the peptide chain.
Antigenic determinants are usually located on the surface
of a protein molecule; hence antibodies are sensitive
probes for structural homologies within this part of a
protein (Margoliash et al., 1970; Proger and Wilson,
1971) .
Kotlarz and Buc (1982) reported the immunological
relationships between the two PFKs from E. coli K12 and
other bacteria.

The major E. coli PFK showed strong

cross-reactivity with PFKs from B. stearothermophilus,

Shigella boydii. Shigella sonnei, Salmonella typhimurium.
Klebsiella pneumoniae and Klebsiella oxytocans.

They

concluded that the major E. coli PFK has strong structural
and functional similarities with PFKs from these
organisms.

Antibody raised against PFK from L. plantarum

cross-reacted with PFKs from B. stearothermophilus.
Streptococcus thermophilus, L. acidophilus, and
Lactobacillus helveticus but not with E. coli PFKs (Simon
and Hofer, 1981).

The close immunologic relationship of

PFKs from B. stearothermophilus and other bacteria implies
the existence of homology in their structures.
Studies on immunological cross-reactivity of
eucaryotic PFKs are not as thorough as those on the
procaryotic enzyme.

Rabbit muscle PFK antibody has a very

low reactivity with the rabbit erythrocyte enzyme (Tarui
et al., 1972).

Cross-reactivity has not been observed

among the three rat PFK isozymes (Dunaway and Kasten,
1987), or among the three human PFK isozymes (Dunaway and
Kasten, 1988).

They have used antibodies to quantify the

amount of PFK subunits in each tissue.
Immunological cross-reactivity may be considered as
an initial step in the structural homology studies among
PFKs from various sources.

The penultimate technique to

comprehend the relationship between structure and
properties of proteins is the determination of their
primary and crystallographic structures which may be

proven unequivocally and ultimately by site-directed
mutations.

Structure of PFK
PFK is active in its tetrameric form.

Each subunit

has a molecular mass of 34,000-87,000 depending on its
source.

The entire amino acid sequence of BsPFK has been

established (Kolb et al., 1980; French and Chang, 1987).
Comparison of its amino acid sequence with PFK from rabbit
muscle and E. coli shows that the eucaryotic PFK has
evolved probably by duplication of the bacterial gene
(Poorman et al., 1984) .
The crystallographic structure of the active form of
BsPFK has been determined to 2.4 A resolution (Evans and
Hudson, 1979).
located.

Three ligand binding sites have been

The Fru 6-P binding site and effector site

(where phosphoenolpyruvate, ADP and GDP bind) are in
between two subunits whereas ATP binding site resides
within one subunit.

The roles of amino acid residues in

these sites have been described in detail and compared
with homologous PFKs from E. coli and rabbit muscle (Evans
et al., 1981; Hellinga and Evans, 1985)

(Table 1).

Some

of these putative amino acid residues have been mutated in
the homologous E. coli PFK.

Mutation of Glu-187 to Ala in

the effector site makes PEP an activator rather than an
inhibitor (Lau and Fersht, 1987) and truncation of Tyr-55

11

Table 1. A comparison of residues in the ligand-binding
sites of three related PFK's: EcPFKA (EC), BsPFK (BS) , and
the N-terminal and C-terminal halves of RMPFK [RM(N) and
RM(C)]. Residues are listed under their number in the
BsPFK sequence. Residues contributing to sites A and C
are divided between neighboring subunits in the tetramer.
Residues marked * are not in the subunit containing the
main part of the site. The dyad symmetry axis relating
the subunit containing these residues to that containing
the main site are given as (p), (q) or (r). (Adapted from
Hellinga and Evans, 1985.)
A. Site A F m l f i P binding

Residue
number

EC

BS

Residue type
RM(N)

125
127
129
162*(r)
169
170
171
222
243*(r)
249
252

T hr
Asp
Asp
Arg
Met
Gly
Arg
Glu
Arg
His
Arg

Thr
Asp
Asp
Arg
Met
Gly
Arg
Glu
Arg
His
Arg

Ser
Asp
Asp
Arg
Met
Gly
Arg
Glu
Arg
His
Arg

EC

BS

Residue type
RM(N)

Gly
T yr
Arg
Plie
Arg
Asp
Gly
Ser
Met
Gly

Gly
T yr
Arg
Cys
Lys
Asp
Gly
Ser
Gin
Gly

Gly
T yr
Arg
Cys
Arg
Asp
Gly
Ser
Tlir
Gly

RM(C)
Thr
Ser
Asn
Arg
Met
Gly
Gly
Glu
Arg
His
Gin

Comments
H bond to 1-phosphate
C atalytic residue, H bond to 0 (31
Binds w ater attached to Mg3+
Binds 6-phosphate
Hydrophobic contact to 0 (2), 0 <3)
Main-chain H bond to Ol3l
Near 1-phosphate
H bond to 0 ,4)
Binds 6-phosphate
Binds 6-phosphate
H bond to 6-phosphate and 0 (2(

B. Site D A DP binding
Residue
number
11

41
72
73
77
103
104
105
107
108

.

RM(C)
Ala
Phe
Arg
T hr
Lys
(Phe)
(Glu)
(Leu)
Glu
Gly

Comments
Main-chain amide H bond to /J-P
Contact to ribose
Bridges A DP a-P and Frul.O P phosphates PI and PC
Main-chain amide and carbonyl H bond to rihose OH
Hydrophobic contact to adenine
Binds to Mg3 *
Main-chain NH H liond to /J-P, no room for side-chain
H bonds to fl-V from OH and XH
Hydrophobic contact to adenine
Contacts adenine

S ite C effector site ( A D P )
Residue
number

EC

BS

Residue type
RM(N)

2 I*(p)
25*(p) ,
54*(I>)
55»(p)
58*<P)
59*(p)
154
185
187
211
213
214
215
C term inus

Arg
Arg
Arg
T yr
Ser
Asp
Arg
Gly
Glu
Lys
Lys
Lys
His
T yr

Arg
Arg
Val
Gly
Gly
Asp
Arg
Gly
Glu
Arg
Lys
Lys
His
He

Arg
Arg
Trp
Glu
Ser
Met
Tlir
Gly
Asp
Thr
Thr
Arg
Gly
—

.

RM(C)
Arg
Arg
T rp
Ser
Gly
Gly
Lys
Gly
Asp
Lys
Lys
T hr
T hr
(Val)

Comments
H bond to /1-P and to Mg3 t-w a ter
H bond to /1-phosphate
H bond to a -P and C terminus
Stacks against adenine ring
H bond to a-P and Arg25
Main-chain amide H bond to /?-P, side-chain H-bond to ribose 0 |3.,
Two If bonds to /1-P
Main-chain carbonyl bonds to Mg3*
Carboxyl binds to Mg3*
A lternative to Arg54
H bond to C terminus and <!lulK7
Main-chain amide H bond to rihose 0 )4-( (side-chain disordered)
Bond to Mg3 * via water
H bond to Arg54 in K. coti

to Gly proves the presence of an interaction between the
aromatic ring of the tyrosine residue with guanine of GDP
(Lau et al., 1987).

Site-directed mutations of Arg-21,

Arg-25, Lys-213, Arg-54, Arg-154 and Asp-59 show that
these residues are involved in the binding of GDP and PEP
(Lau and Fersht, 1988).

Hellinga and Evans (1987) show

that Asp-127 is a key residue in the EcPFKA catalysis
probably acting as a base in the reaction mechanism.

Arg-

162 and Arg-243 have been shown to be important residues
in the T to R transition of this enzyme (Berger and Evans,
1988) .
The crystallographic structure of allosterically
inhibited BsPFK has also been determined to 7 i resolution
(Evans et al., 1986).

It may not be as refined as the X-

ray structure of the active form but it gives a structural
difference between the two conformations: that is, one
subunit twists relative to other subunits about 8°.

This

rotation diminishes the access of Fru 6-P to its binding
site but makes the effector site more accessible to PEP.
This explains the weak binding of Fru 6-P but strong
binding of PEP to the T (tight) conformation of the
enzyme.
The gene encoding BsPFK has been cloned, sequenced
and expressed to high-level in E. coli (French and Chang,
1987; French et al., 1987).

This provides opportunities

to study the structure-function relationships in BsPFK and
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to make a comprehensive comparison between this enzyme and
the major E. coli PFK.
The nucleotide sequence of the rabbit muscle PFK gene
has been reported (Lee et al., 1987)=

The sequence

identifies additional 30 amino acid residues which are not
included in the primary structure of PFK
earlier (Poorman et al., 1984).

published

More recently, the cDNA

sequence of human muscle (Nakajima et al., 1987) and mouse
liver (Gehnrich et al., 1988) PFK have been reported.

The

rabbit muscle PFK gene has higher nucleotide homology with
the human muscle PFK gene than the mouse liver gene.

Site-directed Mutagenesis and Protein Engineering
The rapid advances in the technology of
oligonucleotide synthesis have led to wide applications of
synthetic oligonucleotides in molecular biology.

One of

the powerful techniques that use this tool is sitedirected mutagenesis.

It involves annealing a mutagenic

oligonucleotide primer to a single-stranded DNA template,
extending the primer by DNA polymerization, ligating the
ends, and transfecting competent bacterial cells.
The methodologies and applications of site-directed
mutagenesis have been reviewed in the literature (Smith,
1985; Bolstein and Shortle, 1985; Carter, 1986;
Leatherbarrow and Fersht, 1986).

The approaches for

oligonucleotide-directed mutation have a common strategy:

creation of an asymmetry between two DNA strands to
increase the frequency of mutation.

Some of these

asymmetries employ the use of hemimethylated DNA (Kramer
et a l., 1982; Marmenout et al., 1984), nonsense codons
(Kramer et al., 1984; Carter et al., 1985), restriction
modification systems in E. coli (Carter et al., 1985;
Carter, 1987), y-phosphorothionate dNTP analogue (Taylor
et al., 1985a; Taylor et al., 1985b) and uracil residues
in place of thymine (Kunkel, 1985; Kunkel et al., 1987).
In this dissertation, the use of uracil residues in
place of thymine is employed.

Briefly, a single stranded

uracil-containing M13 DNA template is produced within a
dut" ung“ mutant strain of E. coli.

This strain lacks

dUTPase and uracil N-glycosylase activities; hence uracil
is incorporated into but not removed from the DNA.

The

mutagenic synthetic oligonucleotide primer is annealed
into the uracil-containing template prior to in vitro
synthesis of the second normal strand.

Transfection of

the heteroduplex strands into wild-type dut+ ung+ strain
results in excision of the uracil residues and production
of pyrimidinic (AP) sites thereby preferentially enriching
the strand that carries the mutation.
Early reports on the use of oligonucleotide-directed
mutagenesis to study protein function were on tyrosyl-tRNA
synthetase (Winter et al., 1982),

8-lactamase (Dalbaldie-

McFarland et al., 1982; Sigal et al., 1982; Charles et

al., 1982) and prolipoprotein (Inouye et al., 1982).
Since then the number of proteins modified by this
technique had increased tremendously.
The most common application of mutagenesis in protein
chemistry is the study of the contribution of individual
amino acid residue to enzyme catalysis

and regulation.

It

is possible to elucidate the mechanism

of enzyme catalysis

in a way that no other method allows (Straus et al., 1985;
Fersht et al., 1986).

Mutagenesis may also be used to

localize specific functional zones (Waye et al., 1983;
Bedouelle and Winter, 1986) and to alter physical
properties of a protein (such as thermal stability, pH
optimum, molecular size and subunit composition)

(Wells

and Powers, 1986; Robey and Schachman,

1985).

It is,

therefore, possible to produce enzymes

with novel

properties by protein engineering using oligonucleotidedirected mutagenesis.

Rationale and Objectives
The properties of a protein are dictated by its
structure.

Proteins of related function have been shown

to have common structural features.

NAD-dependent

dehydrogenases, for example, have been shown to have a
common domain of six parallel 8-sheet strands in a 6-a-6
structure (Levitt and Clothia, 1976).

Some DNA binding

proteins have Zn-finger or leucine-zipper structures which

are believed to be essential for nucleic acid binding
(Klug and Rhodes, 1987; Landschulz et al., 1988).

The

importance of these structures can be proven unequivocally
by mutations of certain key amino acid residues involved
in their polypeptide chains.
Phosphofructokinase is one of the enzymes the
properties of which have been thoroughly studied.
However, there are still questions on the relationship
between its function and structure.

BsPFK is a good

system to study and answer some of these questions.

The

BsPFK molecule is smaller compared to other PFKs; hence it
is easier to correlate experimental data with its
structure.

Its thermal stability makes this enzyme easier

to handle.

The availability of its crystallographic

structure provides good structural information including
precise locations of amino acid residues involved in
ligand binding.

BsPFK cross-reacts with antibodies raised

against various PFKs more than any other procaryotic PFKs.
Therefore, structural study on this enzyme may provide
important information on the structure of other
procaryotic PFKs.
Crystallographic studies on BsPFK have shown that
Arg-252 plays a critical role in subunit assembly and
orientation.

It forms hydrogen bonds with both the

substrate of the enzyme, Fru 6-P, and with the adjacent
subunit to stabilize the quaternary structure of the

active tetramer (Evans et al., 1981).

X-ray

crystallograph of allosterically inhibited BsPFK reveals
subunit twisting to limit access to the Fru 6-P binding
site (Evans et al., 1986).

Mutation of Arg-252 may lower

Fru 6-P binding and may weaken subunit interaction.

In

this study, Arg-252 has been mutated to Ala and to Lys to
determine how the length and charge of side chain affects
the magnitude of changes in the properties of the enzyme.
ADP, GDP and PEP bind to the same regulatory site in
BsPFK.

The amino acid residues involved in the binding of

these modulators have been identified from the X-ray
structure of the enzyme (Evans et al., 1981).
residues are Arg-25, Arg-211 and Asp-59.

Among these

Each has been

mutated to Ala to prove that the three residues are
involved in the binding of the activator(s) and inhibitor.
In the homologous rabbit muscle PFK, Asp-59 is replaced by
Met; hence a Met-59 mutant BsPFK has also been
constructed.
The study of transcriptional control in eucaryotic
PFK is of equal importance as the structure-function
relationship in the procaryotic enzyme.

Mammalian PFK has

three types of subunits which associate to form
homotetramer or heterotetramer depending on the abundance
of the subunits in a particular tissue.

These PFK

isozymes exhibit different allosteric behavior, thus they
respond to tissue-specific regulation of glycolysis

(Dunaway and Kasten, 1987).

Understanding the tissue-

specific expression of their genes requires knowledge of
the nucleotide sequence of the different PFK isozyme
genes, especially their promoter regions.

The isolation

of the 5' flanking region of human muscle PFK gene will
help in the study of the cis-regulatory sequence and any
trans-acting factor that might regulate this gene.

This

will also give an insight into its expression in patients
with glycogen storage disease type VII (Vora et al.,
1983).
This study has been conducted with the following
specific aims:
1. To compare kinetic properties of authentic BsPFK,
cloned BsPFK and cloned EcPFKA;
2. To establish conditions for site-directed mutation
in BsPFK and express mutants to high-level;
3. To determine how subunit interaction is affected
by mutation of Arg-252

(located at the Fru 6-P binding

site) to lysine or alanine;
4. To correlate experimental results on Arg-252
mutations with R to T transformation;
5. To mutate Arg-25, Arg-211 and Asp-59 (located at
the allosteric site) and determine their role in the
binding of GDP and PEP; and
6. To clone, sequence and characterize the 5' non
translated region of the human muscle PFK gene.

CHAPTER II
MATERIALS AND METHODS
Materials
A.

Enzymes
Restriction endonucleases were purchased from

Bethesda Research Laboratories (BRL)
England Biolabs, Inc.

(NEB)

(Bethesda, MD), New

(Beverly, MA), Boehringer-

Mannheim Biochemicals (Indianapolis, IN) and Pharmacia
(Piscataway, NJ).

T4 DNA ligase and DNA polymerase I

(Klenow Fragment) were obtained from BRL and NEB.
Sequenase kit was ordered from United States Biochemicals
Corp.

(Cleveland, OH).

RNAse A, aldolase (Type IV),

mixture of triose-phosphate isomerase and glycerol 3phosphate dehydrogenase (Type III) and creatine
phosphokinase were purchased from Sigma Chemical Co.

(St.

Louis, MO).
B.

Chemicals
Bacto-tryptone, bacto-yeast extract, and bacto-agar

were purchased from Difco Laboratory (Detroit, MI).
Agarose, dithiothreitol, urea and phenol were obtained
from BRL.

Acrylamide, N',N-methylene-bisacrylamide,

TEMED, and ammonium persulfate were ordered through BIO
RAD (Richmond, CA).

Low melting point SeaPlaque agarose

was purchased from FMC Corporation (Rockland, ME).
Methanol, ethanol, chloroform and acetic acid were
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purchased from Fisher Scientific (Fair Lawn, NJ) and
American Scientific Products (McGaw Park, IL).
Tris(hydroxymethyl)aminomethane (Tris),
ethylenediaminetetraacetic acid (EDTA), magnesium
chloride, ammonium chloride, nicotinamide adenine
dinucleotide (reduced form, NADH), sodium chloride, sodium
hydroxide, phenylmethylsulfonyl fluoride, Cibacron Blue
3GA-Agarose (Type 3000-CL-L), fructose 6-phosphate (sodium
salt), adenosine triphosphate (sodium salt), adenosine
diphosphate (sodium salt), guanosine triphosphate (sodium
salt), guanosine diphosphate (sodium salt),
phosphoenolpyruvate, creatine phosphate,
polyethyleneglycol (PEG 6000), ampicillin and bovine serum
albumin were obtained from Sigma Chemical Co.
Nitrocellulose filters were purchased from Schleicher and
Schuell (Keene, NH).

Prepared Sephadex G-50 (Select D)

columns were obtained from 5 Prime - 3 Prime, Inc.

(West

Chester, PA) and NACS PREPAC columns from BRL.
Polyethylene imine cellulose F plates were purchased from
EM Science (West Germany).

3MM Whatman filter papers were

ordered from Fisher Scientific.
obtained from Pharmacia.

Films (XAR-5 and XRP-5) were

purchased from Eastman Kodak Co.

C.

ATP-agarose (Type II) was

(Rochester, NY).

Radionucleotides and oligonucleotides
[a-32P]-dATP was purchased from ICN Biochemicals,

Inc.

(Cleveland, OH).

[Y-32P]-ATP and

[a-35s ] thio-dATP

were obtained from New England Nuclear, Inc.

(Boston, MA)

Oligonucleotides were synthesized by solid support
phosphite chemistry (Matteucci and Caruthers, 1981) in an
automated DNA synthesizer (Applied Biosystems Model 380A)

D.

DNA and Bacterial Strains
M13mpl8, Ml3mpl9 and pBR322 were obtained from BRL.

M13Bspfk was constructed by French and Chang (1987).
mHElOll, an M13mp8 clone containing the major E. coli PFK
gene (EcpfkA)

(Hellinga and Evans, 1985), was a gift from

Dr. P. Evans (MRC, Cambridge, UK).

E. coli strains DH5

and DH5 F' competent cells were purchased from BRL.

E.

coli strain DF1020 [a recA derivative of DF1010 (Daldal,
1983): pro-82,

pfkB201, recA56,

(rha-pfkA)200, endAl,

hsdR17, supE44, thi-11 was kindly provided by Dr. Barbara
Bachmann of the E. coli Genetic Stock Center (Yale
University School of Medicine, New Haven, CN).

Bacillus

stearothermophilus NCA 1503 (ATCC 7 954) was obtained from
the American Type Culture Collection (Rockville, MD).

Common Solutions/Reagents
LB (Luria-Bertani) Medium:
Per liter:
Bacto-tryptone
Bacto-yeast extract
NaCl
Adjust pH to 7.5.

10 g
5g
10 g

YT Medium:
Per liter:
Bacto-tryptone
Bacto-yeast extract
NaCl
Adjust pH to 7.5.

10 g
10 g
5 g

Sonication Buffer:
50 mM Tris-Cl (pH 7.4)
1 mM DTT
0.1 mM EDTA
0.1 mM phenylmethylsulfonyl fluoride (PMSF)
(0.1 M PMSF is prepared in ethanol.)
Low-salt Sonication Buffer:
Sonication buffer containing 0.25 M NaCl
High-salt Sonication Buffer:
Sonication buffer containing 1.5 M NaCl.
Lysozyme Solution:
50 mM glucose
10 mM EDTA
25 mM Tris-Cl (pH 8.0)
4 mg/ml lysozyme
Add powdered lysozyme to the solution just before
use.
Tris-EDTA (TE):
10 mM Tris-Cl (pH 8.0)
1 mM EDTA
Tris-Acetate (TAE):
Per liter 50X stock solution:
Tris base
242 g
glacial acetic acid
57.1 ml
0.5 M EDTA (pH 8.0)
100 ml
Tris-Borate (TBE):
Per liter 5X stock solution:
Tris base
54 g
Boric acid
27.5 g
0.05 M EDTA (pH 8.0)
20 ml

Agarose Gel-loading Buffer:
10X stock solution:
0.25 % Bromophenol blue
0.25 % Xylene cyanol FF
25
% Ficoll (Type400) in water
Store at room temperature.
SSC:
20X stock solution:
NaCl
175.3 g
Sodium citrate
88.2 g
H,0
800
ml
Adjust pH to 7.0 and complete the volume to 1 liter.
Sterilize by autoclaving.
Denhardt's Solution:
50X stock solution:
Ficoll
5 g
Polyvinylpyrrolidone
5 g
BSA
5 g
H20
to 500 ml
Filter through 0.45-um membrane and store at -20°C.
Medium-salt Digestion Buffer:
10X stock solution:
100 mM Tris-Cl (pH 7.5)
500 mM NaCl
100 mM MgCl2
10 mM DTT

Subcloning and Expression of BsPFK
BsPFK gene was subcloned from M13Bspfk (French and
Chang, 1987) to pBR322 and expressed to high level in E.
coli as described by French et al. (1987) .

A.

Rapid Preparation of DNA
M13Bspfk RF DNA was prepared similar to the alkaline

lysis method described by Maniatis et a l . (1982).

An

overnight culture of JM107 was diluted 50-fold with 2X YT
medium.

Four ml of this suspension was infected with 0.5

ul M13Bspfk phage and incubated for 5 1/2 hours at 37°C on
a roller shaker.

The cells were harvested by spinning for

10 min using a microcentrifuge tube.

Using a drawn-out

pipet the supernatant was sucked with vacuum.
spun for 30 seconds and any liquid was removed.

It was re
Each

pellet from the original 1.5 ml cell culture was suspended
in 100 ul freshly prepared ice-cold lysozyme solution and
was vortexed for 2 min.

It was stored at room temperature

for 5 min and 200 ul of 0.2 N NaOH/1% SDS solution was
added.

Cell lysis was facilitated by inverting the tube

three or four times and was held on ice for 5 min.
Proteins were precipitated by adding 150 ul chilled
potassium acetate solution (pH 4.8), prepared by mixing
6.0 ml of 5 M potassium acetate, 1.15 ml acetic acid and
2.85 ml H20.

The tube was inverted three to four times

and stored on ice for 5 min.

The denatured proteins were

separated by spinning for 5 min and 0.40 ml supernatant
was carefully transferred to a fresh tube avoiding the
white precipitate.

Unprecipitated proteins were extracted

at room temperature by adding 0.40 ml of phenol/CHCl3
mixture (1:1) by vortexing for 2 min, spinning for 3 min
and transferring the top aqueous phase to a fresh tube
avoiding the interface.

This was further extracted with

0.4 ml CHC13 by vortexing 'for 2 min, spinning for 3 min

and transferring the aqueous phase to a fresh tube.

The

DNA was precipitated with 0.8 ml ethanol for 2 min at room
temperature.

It was spun for 2 min and the supernatant

was aspirated completely.

The pellet was further cleaned

by dissolving in 100 ul of 0.3 M sodium acetate (pH 5.2)
and adding 250 ul ethanol.

After 2 min at room

temperature the DNA was pelleted by spinning for 2 min and
the supernatant was removed completely.

One ml of 70 %

ethanol (room temperature) was added, vortexed for 1 min,
spun for 1 min and the supernatant was removed.

The DNA

pellet was vacuum dried for 5 min and dissolved in 50 ul
of TE buffer containing DNAse-free RNAse A (10 ug/ml).

B.

Digestion of DNA
Thirty ul of M13Bspfk RF DNA (from rapid preparation)

was digested with 20 units Hindlll in a medium-salt buffer
containing 0.1 ug/ul BSA for 2 hrs at 37°C.

The final

volume was 80 ul.

This was heated at 80-85°C for 5 min to

denature Hindlll.

After cooling to room temperature, the

NaCl concentration was adjusted to 100 mM and 20 units
EcoRI were added.
another two hours.

Incubation at 37°C was continued for
pBR322 (10 ug) to be used as a vector

was digested with Hindlll and EcoRI following the same
procedure.
Both digests were run on a 1 % low melting point
SeaPlaque agarose (FMC Biochemicals) in IX TEA buffer at

75 volts until the fast moving dye reached the bottom of
the gel.

DNA bands were visualized with ethidium bromide

(0.5 ug/ml) in TAE buffer.
The 2.5 kb Bspfk

and the pBR322 bands were cut out of

the gel and were purified using NACS PREPAC column
following the procedure recommended by the supplier.
Briefly, the gel slice was placed in an Eppendorf tube and
melted at 70°C water bath.

Four volumes of 0.625 M NaCl

in TE buffer was added and the diluted gel mix was
incubated at 70°C for 10 min.

This was transferred to a

40°C water bath for 10 min and loaded at once onto a
PREPAC column previously equilibrated with 0.5 M NaCl in
TE buffer.

The bound

DNA was washed with the same buffer

(5 ml) and was eluted
buffer, three times.

with 0.1 ml of 2 M NaCl in TE
The effluents were pooled and 10 ug

tRNA plus 0.6 ml of cold (-20°C) 95 % ethanol were added.
The samples were cooled down to -70°C for 10 min and
centrifuged for 15 min.

The pellet was washed carefully

with 80 % ethanol (-20°C) , vacuum dried for 5 min, and
resuspended in 20 ul TE buffer.

C.

Ligation
The following is an example of a ligation reaction:

BRL 5X ligation buffer (4 ul), H20 (5 ul), purified
Hindlll/EcoRI digested pBR322 (5 ul), purified Bspfk
fragment (5 ul), and BRL 1 U/ul ligase (1 ul).

This was

incubated overnight at 15°C.

D.

Transformation of DH5a Cells
E. coli DH5a competent cells were used in the

transformation following the protocol provided by the
supplier (BRL)

(Appendix 1).

Ten representative

transformants were picked up with sterile tooth picks and
each was used to inoculate 4 ml LB medium containing 50
ug/ml ampicillin.

The plasmid was isolated following the

previously described procedure for RF DNA preparation.

To

check for size of the insert, the recombinant plasmid DNA
was digested with Hindlll and EcoRI as described before.

E.

Transformation of DF1020 Cells
DF1020, a pfk-negative E. coli strain, was prepared

according to the FSB method of Hanahan (1983)
2).

(Appendix

This was transformed with pBR322/Bspfk similar to the

transformation of DH5

cells.

One ul of 10-fold diluted

pBR322/Bspfk DNA was used to transform 30 ul DF1020
competent cells.

Ten representative recombinants were

checked for size of insert as described above.

Purification of Cloned BsPFK
A. Growing of Cells and Sonication
A colony of transformed DF1020 was used to inoculate
5 ml 2X YT broth containing 100 ug/ml ampicillin.

This

was incubated overnight at 37°C on a roller shaker.

A

portion of the overnight culture (1.5 ml) was mixed with
500 ml 2X YT medium containing 100 ug/ml ampicillin.
was incubated at 37°C on a rotary shaker (250 rpm).

This
After

14 hrs of incubation, a 1.5 ml sample aliquot was obtained
to assay for PFK activity.

Briefly, the cells in the

aliquot was spun down using an Eppendorf centrifuge.

This

was resuspended in 0.5 ml sonication buffer and sonicated
on ice for 1 min using Sonicator Ultrasonic Cell Disruptor
Model W-225R (Heat Systems-Ultrasonics, Inc., Farmingdale,
NY) with the following settings: pulse, level 6, 50 %,
microtip.

The cell extract was centrifuged at 4°C for 5

min and the supernatant was assayed for PFK activity as
described below.

This sampling for PFK activity was

repeated every 2 hrs until the activity reached at least
10 U/ml of crude extract.
Cells were then pelleted by centrifugation at 4°C,
5,000 Xg for 10 min using Sorvall Centrifuge RC2-B.

(The

cells can be stored at -20°C without appreciable loss in
activity.)

The cells were weighed and resuspended at 10 %

in sonication buffer.

The cell suspension in plastic

centrifuge tube was sonicated (pulse, 50 %, level 6, horn
tip) at 0°C

for 1 min. This was

min cooling interval.

repeated 5 times with 1

The crude lysate was centrifuged

for 1 hr at 12,000 Xg, 4°C.

The

supernatant was saved and

the residue was resuspended in 10 ml sonication buffer.

This second cell suspension was sonicated as described
above 3 times, centrifuged and the supernatants were
pooled together.

B.

Heat Treatment
The clear supernatant solution was heated at 70°C for

15 min, cooled on ice, and centrifuged for 1 hr at 12,000
Xg, 4°C.

Longer heating was sometimes used but a prior

small scale heat treatment was done.

Sample of 0.5 ml was

put in an Eppendorf tube, heated at 70°C water bath, and
aliquoted 0.1 ml for PFK assay after 15, 30, 45, and 60
min.
The heated sample was adjusted to 0.25 M NaCl by
adding appropriate amount of 5 M NaCl (2.7 ml of 5 M NaCl
per 50 ml sample).

The concentrated NaCl solution was

added drop by drop while stirring the sample gently at 4°C
to prevent protein denaturation.

C.

Column Chromatography
Cibacron Blue 3GA-Agarose (12 g) was suspended in

sonication buffer and gently stirred at 4°C to break any
clumps for at least 1 hr.

The resin was transferred into

a BIO-RAD yellow column (30 X 1.5 cm) without trapping air
bubbles.

The resin was equilibrated at 4°C with low-salt

sonication buffer using a peristaltic pump at the rate of
0.35 ml/min.

This was usually done overnight.

The

conductivities of the equilibration buffer and the eluate
were compared to determine if the resin was equilibrated.
The sample was loaded onto the column maintaining the same
flow-rate of 0.35 ml/min.

The column was washed with low-

salt sonication buffer until the absorbance of the eluate
at 280 nm was almost zero.
A linear salt gradient was used to elute BsPFK.

The

inner cylinder of BRL gradient former was filled with 85
ml low-salt sonication buffer and the outer chamber was
filled with equal volume of high-salt sonication buffer.
While stirring the inner chamber, the buffer was pumped
into the column.

Each fraction collected was about 2.8

ml.

The absorbance of each fraction was measured at 280

nm.

PFK activity was determined using the standard assay

condition described below.

The purity of all active

fractions was determined using a 12.5 % SDS-PAGE (Appendix
7) .

D.

Glycerol Concentration
Fractions containing pure BsPFK were pooled and

transferred to a clean dialysis tube (3/4 inch diameter).
This was dialyzed against 50 % glycerol in sonication
buffer in 1 liter graduated cylinder stirred at 4°C.
After 4 hrs, the orange clamp that sealed the dialysis
tube was adjusted to the reduced volume of the active
fraction.

This was transferred to a 2-liter sonication
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buffer and stirred at 4°C to remove NaCl and glycerol.
After 4 hrs, the tube was dialyzed again against 50 %
glycerol.

This cycle of concentration and removal of

glycerol was repeated until the volume of PFK solution was
reduced to 1.5 - 2 ml.

The last dialysis step was against

50 % glycerol so that the sample may be stored at -20°C.

Purification of Authentic BsPFK
Native or authentic BsPFK

was isolated from B.

stearothermophilus strain NCA 1503.

A colony was used to

inoculate 25 ml of LB medium and was incubated at 57°C
overnight by using a rotary shaker at 25 rpm.

This was

scaled up by seeding 500 ml LB with 5 ml of overnight
culture and incubating at 57°C until the optical density
at 700 nm reached 0.8 (late log phase) to prevent
sporulation.

The authentic BsPFK was purified in the same

way as the cloned BsPFK except using a different resin in
the column chromatography.
Agarose coupled to N 6 - (6-aminohexyl)-adenosine 5'triphosphate (ATP-Agarose) was obtained as a suspension.
About 10 ml was transferred in a BIO-RAD column (20X1 cm)
and equilibrated with low-salt sonication buffer as
described by Kolb et al. (1980).

The sample, adjusted to

0.25 M NaCl, was loaded on the column, washed with the
same buffer at a flow-rate of 0.35 ml/min.

When the

absorbance of the eluate at 280 nm was almost zero, the

bound enzyme was eluted with 50 uM Fru 6-P in low-salt
sonication buffer.

Fractions which showed PFK activity

was pooled and concentrated with glycerol as described
above.

Expression and Purification of EcPFKA
EcPFKA gene in mHElOll was subcloned in the Hindlll
site of pUC18 similar to the subcloning of Bspfk from
M13Bspfk to pBR322 as previously described.

Expression in

DF1020 and large scale preparation of the culture and the
crude extract were similar to that of BsPFK without
heating the extract.
The crude lysate was further purified using Cibacron
Blue 3GA-Agarose similar to that of BsPFK except for minor
modifications.

The column was equilibrated with

sonication buffer, the sample loaded and washed with
sonication buffer containing 1.5 M NaCl.

Finally, EcPFKA

was eluted using 2 mM ATP/10 mM MgCl2 in sonication
buffer.

Absorbance of the fractions at 280 nm was not

measured due to the interference of absorbance of ATP.
However, these were assayed for PFK activity and the
active fractions were pooled and concentrated using Amicon
ultrafiltration cell (Amicon Corp., Danver, MA).

Purification and Phosphorylation of Synthetic
Oligonucleotides
Oligonucleotide in concentrated NH^OH incubated for
15 hrs at 50°C was evaporated to dryness using SpeedVac
Concentrator (Sarvant Instruments, Farmingdale, NY).
was dissolved in 2.5 ml of 25 mM TEAB

It

and then loaded

into a SEP-PAK column previously washed with 10 ml of
CH3CN, 10 ml of 30 % CH3CN in 25 mM TEAB, and 20 ml of 25
mM TEAB.

The bound oligonucleotide was washed with 4 0 ml

of same buffer or until there was no absorbance at 260 nm.
This was followed with 5 ml of 10 % CH3CN, 5 ml of 30 %
CH3CN and 5 ml of 50 % CH3CN (all in 25 mM TEAB) ; the
washings were saved separately.

Each was tested for

dimethyltrityl group (DMT) by spoting on silica TLC plate
(Uniplate)

(Analtech, Inc., Newark, DE).

On top of each

spot, a drop of 0.1 M p-toluene sulfonic acid in CH3CN was
added.

The plate was heated until the orange color

appeared.

The fraction that gave the brightest orange

color was dried under vacuum.

DMT was removed by

dissolving it in 1 ml 80 % acetic acid and incubating at
room temperature for 25 min.
was evaporated to dryness.
and dried again.

The slightly pink solution
It was redissolved in 1 ml H20

This was done three times.

It was

dissolved in 200 ul water, quantitatively transferred to a
siliconized Eppendorf tube and lyophilized.

The residue

was dissolved in 100 ul H20 and 100 ul FDE (80 %
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formamide, 10 mM NaOH, 1 mM EDTA, 0.1 % Bromophenol blue,
0.1 % Xylene cyanol FF) prior to polyacrylamide gel
electrophoresis.
Polyacrylamide gel was prepared by adding 15 ul TEMED
and 80 ul of 50 .% ammonium persulfate to 100 ml gel
solution (20 % acrylamide, 1 % bisacrylamide, 8 M urea and
in TBE buffer).

It was pre-run at 30 mA for 1 hr.

The

sample was loaded and run at the same condition until the
fast moving dye reached an inch above the bottom of the
gel.
The gel was put on top of a fluorescent plate and the
DNA band was visualized with short wavelength UV lamp.
The band was excised and crushed to a fine powder in a
polypropylene tube with siliconized glass rod.

It was

suspended in 6 ml of 1 M TEAB and was shaken at 37°C
overnight.

It was filtered on a siliconized sintered

glass and the filter was washed with 10 ml H20 three
times.

The pooled filtrate was passed through a washed

SEP-PAK column.

The bound DNA was washed with 30 ml of 25

mM TEAB and eluted with 5 ml of 30 % CH3CN in 25 mM TEAB.
It was vacuum dried as before, dissolved in 5 ml H20,
dried again (3X) and the concentration was determined at
260 nm.
To test the quality of the synthetic oligonucleotide,
it was end-labeled with 32P.

One ug DNA in 70 mM Tris-Cl

(pH 7.6), 10 mM MgCl2, 5 mM DTT was mixed with [Y-32P]ATP

and T4 polynucleotide kinase (20 units).
incubated

This was

at 37°C for 30 min and the incorporation of the

label was tested by thin layer chromatography
(polyethylene imine plate and 0.75 M sodium phosphate, pH
3.5) .
The same procedure was followed for phosphorylation
of mutagenic synthetic oligonucleotide but unlabled ATP
was used.

The phosphorylated oligonucleotide was purified

using prepacked Sephadex G-50 from 5 Prime - 3 Prime, Inc.
The DNA was ethanol precipitated, vacuum dried and
dissolved in 20 ul of 10 mM Tris-Cl (pH 8.0).

Site-directed Mutagenesis
A.

Preparation of Uracil-containing Template
The recombinant M13Bspfk phage was used to prepare

the uracil-containing single-stranded template for the
oligonucleotide-directed in vitro mutagenesis as described
by Kunkel et al. (1987) with minor modifications.

The

phage suspension was heated at 60°C for 5 min and spun for
2 min to kill and remove E. coli cells.

This mixture (3

ul) was added to 30 ml of 2X YT medium inoculated with 1.5
ml mid-log E. coli BW313 in 250 ml Erlenmeyer flask
containing 9 ug uridine.

This was incubated for 5 1/2 hrs

at 37°C.
The cells were separated by centrifugation at 5,000 X
g, 4°C for 10 min.

Phage were precipitated from the clear

supernatant by adding 6 ml (one-fifth volume of the
supernatant) of 20 % PEG 6000/2.5 M NaCl.

This was mixed

well and incubated for 30 min at room temperature.

The

precipitate was collected by spinning at 5,000 Xg for 15
min at room temperature.

The supernatant was poured off

and the tube was respun.

The residual supernatant was

completely removed and the phage was resuspended in 1.5 ml
TE buffer, pH 8.0 by vigorous vortexing.

The suspension

was transferred into a polypropylene tube and 1.5 ml
phenol/CHC13 (1:1) was added.

This was vortexed for 2

min, stored for 5 min at room temperature, vortexed again
and centrifuged for 5 min using a clinical centrifuge.
The aqueous phase was transferred carefully into a fresh
tube and equal volume of CHC13 was added.

This was

vortexed for 2 min, spun for 5 min, and the upper layer
was transferred to a Corex tube.

The DNA was precipitated

by adding 0.1 volume of 3 M sodium acetate (pH 5.2) and 2
1/2 volumes of ethanol.

This was stored at -20°C

overnight or at -70°C for 30 min prior to spinning at 4°C
for 20 min.
ethanol

The pellet was washed with 1 ml of 80 %

(-20°C) and then dried under vacuum for 5 min.

was dissolved in 200 ul TE buffer.

The DNA concentration

was determined at 260 nm using an extinction coefficient
of 27.8 O.D.-ml/mg-cm (i.e. 1 OD26Q = 36 ug/ml) .
purity of the DNA
electrophoresis.

It

The

was examined by agarose (0.8 %) gel

B*

In vitro DNA Synthesis
To 10 ng of phosphorylated oligonucleotide carrying

the mutation was added 1 ug of uracil-containing single
stranded template, 1.8 ul TM buffer (100 mM Tris-Cl, 50 mM
MgCl2, pH 8.0) and H20 to 15 ul total volume.

This was

incubated at 65°C for 30 min and allowed to anneal at room
temperature for 10 min.
The following is an example of the synthesis of the
second strand:
Reagent
Volume (ul)
Annealing Mix
10.0
0.1 M HEPES (pH 7.8) buffer
10.0
50 mM DTT
2.4
1 M MgCl,
0.5
25 mM dNTPs mix (A, C, G, T: each
is 25 mM)
1.0
10 mM ATP
5.0
DNA pol I (Klenow) (1 U/ul)
1.5
T4 DNA ligase (1 U/ul)
3.0
H20
16.6
The mixture was put on ice for 5 min, at room temperature
for another 5 min and then at 37°C for 1 1/2 hr.

The

reaction was stopped by heating at 80°C for 5 min.

The

synthesis was checked by agarose (0.8 %) gel
electrophoresis.
C.

Transformation of DH5aF'
The synthesized double-stranded DNA was diluted 5-

fold, 10-fold, and 50-fold with 10 mM Tris-Cl (pH 8.0).
One ul of the undiluted and diluted DNA was used to
transform DH5«F' competent cells according to the
supplier's protocol (Appendix 3).

D.

Screening for Mutants
Mutants were identified either by sequencing

representative recombinants or by screening plaques with
32P-labeled mutagenic oligonucleotide as hybridization
probe.
Randomly selected recombinants were picked up from
the plate.

These were sequenced according to the

procedure described in Appendix 4 but using one reaction
mix only.

The selected reaction mix was one of the

mutated nucleotides to see the difference between the
mutant and the wild type (control).
The plaque hybridization screening is described in
Appendix 5.

This is a more tedious procedure but gives

better chance of identifying the mutant.
mutant has to be sequenced, too.

The selected

The primers used for in

vitro mutation and DNA sequencing are shown in Appendix 6.

DNA Sequencing
Single-stranded template DNA for sequencing was
prepared similar to the preparation of the template for
site-directed mutagenesis except for the absence of
uridine, use of DH5aF' instead of BW313, and half scale.
Each entire mutated BsPFK gene was sequenced by dideoxychain termination method (Sanger et al., 1977; Biggin et
al., 1983) using a Sequenase kit (USBC) to check that no
other mutations had occured.

The procedure and the

primers used for sequencing are in Appendixes 4 and 6,
respectively.

Assay of PFK Activity
PFK was dialyzed against 1 liter of dialysis buffer
(50 mM Tris-Cl, 0.5 mM DTT, 0.1 mM EDTA, pH 7.4) for 36
hrs at 4°C (two changes).

The enzyme solution was

appropriately diluted with 100 mM Tris-Cl/0.1 mM DTT (pH
8.2 ) prior to enzyme assay.

Auxiliary enzymes were mixed

(112 mg aldolase, 2.4 mg glycerol 3-phosphate
dehydrogenase, 18 mg triose-phosphate isomerase) and
dialyzed against 1 liter of 100 mM Tris-Cl (pH 8.2) at 4°C
for at least 24 hrs (buffer changed twice).

Creatine

phosphokinase solution (1 ug/ul) was always prepared fresh
in 25 mM Tris-Cl (pH 8.2) .

The pH of ATP, ADP and GDP

solutions were adjusted to 7.0 and the actual
concentrations were determined spectrophotometrically.
Phosphoenolpyruvate and creatine phosphate solutions were
prepared in 25 mM Tris-Cl (pH 8.2).
PFK activity was measured by an assay coupled to NADH
oxidation (Babul, 1978; Lau et al., 1987).

One ml of

reaction mixture contained 0.1 M Tris-Cl (pH 8.2), 10 mM
Mgci2, 5 mM NH Cl, 0.2 mM NADH2, 112 ug aldolase, 18 ug
triose-phosphate isomerase and 2.4 ug glycerol 3-phosphate
dehydrogenase.

The standard assay procedure contained 1

mM ATP and 1 mM Fru 6-P.

To prevent ADP-mediated effects,

ATP was regenerated with 1 mM creatine phosphate and 10
ug/ml creatine phosphokinase.

This regenerating system

was omitted whenever the effects of ADP or GDP were
studied.

The NADH oxidation was monitored at 340 nm using

Gilford Response I spectrophotometer at 29°C.
definition,one unit of activity is the

By

amount

of PFK that

catalyzes the conversion of one umole of Fru 6-P to Fru
1,6-P2 per min.
The following was an example of standard assay
protocol:
(1) Warm mix good for 100 assays:
Stock solution
1 M Tris-Cl (pH 8.2)
1 M MgCl 2
1 M NH^Cl
20 mM NADH
H20

Volume (ml)
10.0
1.0
0.5
1.0
81.5

The pH of the warm mix was checkedprior to adding the
required volume of deionized water.

This was maintained

at 29°C during the assay and 0.94 ml aliquot was used per
assay.
(2) Each assay contained:
Reagent
0.1 M Fru 6-P
0.1 M ATP
0.1 M creatinephosphate
1 ug/ul creatinephosphokinase
Auxiliary enzymes
PFK (diluted)

Volume (ul)
10
10
10
10
10
10

Enzymes were always kept on ice except for the diluted PFK
which was more stable at room temperature.

Other reagents

were at room temperature during the experiment.
reaction was initiated by adding PFK solution.

The
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The effect of pH on BsPFK activity was determined
using the following buffered solutions: 0.1 M Imidazole-Cl
(pH 7.0), 0.1 M Tris-Cl (pH 7.4), 0.1 M Tris-Cl (pH 7.8),
0.1 M Tris-Cl (pH 8.2) and 0.1 M Tris-Cl (pH 8.7).

Determination of Kinetic Parameters
Kinetic parameters were calculated using the
Enzfitter Program by Leatherbarrow (1987) on a personal
computer.

The dissociation constant for PEP was

calculated according to Blangy et al. (1968) .

Cloning and Sequencing of Human Muscle PFK Gene
Purification of human DNA from liver and construction
of a genomic library in lambda EMBL4 phage vector followed
a previously described protocol
Sosa and Cohen, 1988).

(Kaiser and Murray, 1985;

Phage plaques equivalent to one

genomic copy (approximately 300,000 plaques) were screened
for human muscle PFK gene following the described
procedure (Maniatis et al., 1982).

The probes used in

this screening were nick-translated M13mpl8 RF DNA
containing rabbit PFK fragments.

The purified human

muscle PFK gene was characterized by its specific
restriction sites followed by nitrocellulose hybridization
with nick-translated phage RF DNA containing the 5' region
of RMPFK gene or an end-labeled oligonucleotide

complementary to codons No. 2 to 8 in the first exon of
the RMPFK gene as probes.

The nitrocellulose filters were

washed either at a stringency of IX SSC, 68°C using the
nick-translated probe, or at IX SSC, 60°C using the endlabeled probe.

The fragments selected from the human PFK

gene were subcloned in M13mpl8 and M13mpl9 phage vectors.
DNA sequence analyses were carried out using the
dideoxynucleotide chain-terminating method (Sanger et al .,
1977) and [ a -35S]thio-dATP (Biggin et al., 1983).
Primers used in these DNA sequence analyses were universal
M13 primer and oligonucleotdes corresponding or
complementary to the coding strand of RMPFK gene.

To

obtain more readable bands I used 50 cm buffer gradient
polyacrylamide sequencing gels (Biggin et al., 1983).
top 10 cm was cut away before autoradiography.

DNA

sequence data were processed using the PCS program
(Lagrimini et al., 1984) on an IBM Personal Computer.

The

CHAPTER III
COMPARISON OF CLONED BsPFK, AUTHENTIC BsPFK AND EcPFKA
Comparison of the Cloned and the Authentic BsPFK
SDS-PAGE shows that the authentic and the cloned
BsPFK's have the same molecular weight (Figure 1).
kinetics study proves that they are identical.

Enzyme

They

exhibit the same hyperbolic profiles with respect to Fru
6-P or ATP concentration (Figures 2 and 3) from pH 7.0 to
pH 8.7.

Highest activity is observed at pH 8.7; however,

succeeding PFK assays are done at pH 8.2 which is close to
the physiological value.

Comparison of BsPFK and EcPFKA
Since both the authentic and the cloned BsPFK do not
show sigmoidal behavior with respect to Fru 6-P, in
contrast with the data previously reported for BsPFK
(Evans et al., 1981), cloned BsPFK and cloned EcPFKA are
compared to settle this discrepancy.

In the absence of

GDP, EcPFKA exhibits sigmoidicity with respect to Fru 6-P
concentration whereas BsPFK shows a hyperbolic profile
(Figure 4).

Addition of GDP causes EcPFKA to exhibit a

hyperbolic behavior.

BsPFK is not activated by GDP per se

and it exhibits a sigmoidal curve only in the presence of
PEP.

ATP is a weak inhibitor of BsPFK at low Fru 6-P

concentrations and this inhibition can be overcome by high
concentrations of Fru 6-P, GDP or ADP (Figure 5).

43

EcPFKA

Figure 1. Relative electrophoretic mobilities of BsPFK's.
Samples of cloned (lane 2) and authentic (lane 3) BsPFK
were loaded on 12.5 % SDS-PAGE and stained with Coomassie
Blue. Lane 1: molecular weight (MW) markers; kd,
kilodaltons
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Figure 2. Dependence of BsPFK activity on Fru 6-P
concentration at various pH's. Initial velocities were
measured using 1 mM ATP and the indicated concentrations
of Fru 6-P for both authentic (A) and cloned (B) BsPFK.
Assay mixes had pH of 7.0 (□), 7.4 ( + ), 7.8 (O), 8.2
(A) and 8.7 (X ) using the buffers listed under Materials
and Methods. Relative activities are relative to the
maximal activity at pH 8.7.
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Figure 3. Dependence of BsPFK activity on ATP
concentration at various pH's. Initial velocities were
measured using 1 mM Fru 6-P and the indicated
concentrations of ATP for both authentic (A) and cloned
(B) BsPFK. Assay mixes had pH of 7.0 (0), 7.4 ( + ), 7.8
(O), 8.2 ( a ) and 8.7 (X) using buffers listed under
Materials and Methods. Relative activities are relative
to the maximal activity at pH 8.2.

Relative Activity

51

1.00

0.90 0.80 -

Relative Activity

0.70 0.60 0.50 0.40 0.30 0.20

-

0.10

-

0.00
0.00

0.40

0.20
[ATP], mM

0.60

Figure 4. Comparison of the effect of Fru 6-P
concentration on the activity of BsPFK and EcPFKA.
Initial velocities were measured in the absence ( • ,
BsPFK; ▲ , EcPFKA) or in the presence ( o , BsPFK;
A, EcPFKA) of 0.5 mM GDP as described under Materials and
Methods using 1 mM ATP and the indicated concentations of
Fru 6-P. Relative activities are based on the maximal
activity of each enzyme in the absence of GDP for BsPFK
and in the presence of GDP for EcPFKA.
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Figure 5. Dependence of wild type activity on ATP
concentration in the absence or presence of an effector at
two levels of Fru 6-P concentrations. Initial velocities
were measured using 0.05 mM (A) and 1 mM (B) Fru 6-P and
other conditions described under Materials and Methods.
Relative activities were relative to the maximal velocity
using 1 mM Fru 6-P in the absence of an effector. □ , no
effector; + , 0.5 mM GDP; O ,0.5 mM PEP; A , 0.5 mM GDP +
0.5 mM PEP.
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is insensitive to ATP inhibition (Blangy et al., 1968).
Observed difference in the behavior of these two
purified enzymes are not due to purification differences.
BsPFK is adjusted to 2 mM ATP and 10 mM MgCl2 and dialyzed
against the same buffer (0.1 mM Tris-Cl, pH 7.4, 1 mM DTT)
used for EcPFKA prior to enzyme assay.

Moreover, crude

extracts of the two enzymes exhibit the same behavior as
the purified ones.

The hyperbolic behavior of BsPFK with

respect to Fru 6-P observed in this study is similar to
that of the PFK from other thermophilic bacteria, e. g.
Flavobacterium thermophilum (Yoshida, 1978) and
Streptococcus thermophilus (Simon and Hofer, 1981), and
PFK from Bacillus licheniformis (Marschke and Bernlohr,
1982) and Lactobacillus plantarum (Simon and Hofer, 1977).
BsPFK requires 5 mM NH4+ for maximal activity.

K+,

but not Na+, may be used as a substitute and a much higher
concentration is required (Figure 6).

This requirement

for NH„+ is similar to EcPFKA and PFK from other sources
(Abrahams and Younathan, 1971; Simon and Hofer, 1977;
Fordyce et al., 1982; Marschke and Bernlohr, 1982).

Discussion
Post-translational modification is common in
eucaryotic proteins but not in procaryotic proteins.

This

is one problem that confronts molecular biologists when
attempting to clone a gene of a particular enzyme and

Figure 6. Effect of ammonium and potassium ion
concentration on the activity of BsPFK. (A) Assays were
conducted as described under Materials and Methods using 1
mM ATP, 1 mM Fru 6-P and indicated concentration of
ammonium ion.
(B) The effects of potassium and ammonium
ions on BsPFK activity were compared. Assays were
conducted using 1 mM ATP, indicated concentration of Fru
6-P, and varying concentration of potassium and ammonium
ions. P , 5 mM K+ ; +, 10 mM K+; O, 5 mM NH+. Relative
activities were relative to maximal velocity using 5 mM
NH+.
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express it to a high level in a system different from its
origin.

In vivo phosphorylation of PFK from rabbit

muscle, for example, probably regulates its activity
(Kitajima et al., 1983).

It is, therefore, important to

always compare the cloned and the authentic enzymes and be
certain that the two are identical.
The relative mobility in SDS-PAGE and enzyme kinetics
prove that the cloned and the authentic BsPFK are
identical.

It suggests that there is no post-

translational modification in BsPFK expression.
The availability of purified cloned BsPFK paves the
way for a thorough kinetic study of this enzyme.

Although

its crystallographic structure is known (Evans and Hudson,
1979), its kinetic properties, however, are not as wellstudied as EcPFKA.

Literature on procaryotic PFK

discusses the kinetic characteristics of EcPFKA while
using the structural details from BsPFK as a model
(Fersht, 1985).
An important difference in the behavior of BsPFK and
EcPFKA is found in this study.

BsPFK has been reported

previously to resemble EcPFKA which exhibits a sigmoidal
profile with respect fo Fru 6-P, and shows ADP or GDP
activation and PEP inhibition (Kolb et al., 1980; Evans et
al., 1981).

Results of this study confirm the kinetic

characteristics of EcPFKA, but reveal that BsPFK exhibits
significant differences.

Specifically, in the absence of

PEP, BsPFK has a hyperbolic kinetic profile with respect
to Fru 6-P and it is not activated by ADP or GDP.

CHAPTER IV
MUTATION OF ARG-252 TO ALANINE AND TO LYSINE
Mutation, Expression and Purification
A common problem in the Kunkel method (Kunkel, 1985)
of site-directed mutation is partial deletion of the
insert during template preparation.

This may be due to

recombination, inherent instability of the insert and/or
the presence of deoxyuridine in the DNA.

Using an M13

multiplicity of infection of no more than 1 and incubating
at 37°C for not more than 5.5 hrs apparently eliminates
the problem of insert deletion (Figure 7) and results in
an overall 30 % in vitro mutation rate.

The mutants are

selected either by lifting all the plaques with
nitrocellulose filter or by sequencing randomly selected
plaques (Figure 8).

The plaque hybridization screening

technique is more laborious but provides higher chance of
identifying the mutant.
The first amino acid residue that has been mutated in
this study is Arg-252, a residue that interacts with the
substrate Fru 6-P and forms hydrogen bonds with the other
subunit (Figure 9).

It has been mutated to lysine and to

alanine and the nucleotide sequences are shown in Figure
10.

The in vitro mutation, subcloning and expression of
BsPFK gene using pBR322 as an expression vector are shown
in Figures 11 and 12.

The 2.5 kb Bspfk fragment contains
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Figure 7. Insert deletion during the preparation of
uracil containing sincrle-stranded DNA. E. coli BW313 was
infected with M13Bspfk phage using the indicated
multiplicity of infection and was incubated at 37°C for
the specified length of time in the presence of uracil.
The uracil containing single-stranded DNA was purified and
loaded into 0.8 % agarose gel and visualized under UV
light by ethidium bromide staining. Lane 1, lambda DNA
cut with HindiII and EcoRI; lane 2, template DNA obtained
using an MOI of 1 and incubation of 5 1/2 hours; lane 3 ,
template DNA obtained using an MOI of 3 and incubation
time of 6 hours.
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Figure 8. Methods of screening for mutants. (A) Track
sequencing was used to identify DM59 mutant (Asp59 -*■
Met). BsPRl8 (Appendix 6) was used as a primer to do a
ddT sequencing reaction on wild type (lane 1) and six
randomly picked plaques (lanes 2-7) and these were loaded
on a 6 % sequencing gel. The arrow shows the two mutants
identified (lanes 3 and 4).
(B) Plaque hybridization
screening using
32P-labeled Bs211 (Appendix 6) to
identify RA211 mutant (Arg211 -> Ala) as described under
Materials and Methods. Only the mutant plaques (m in 1)
hybridized with the probe as shown by the autoradiogram (m
in 2). Plaques which did not hybridize (w in 1) were
considered wild type.
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Figure 9. The binding site for Fru 6-P. The residues
from the two subunits are drawn with solid and open bonds.
Arg-252 interacts with Fru 6-P and forms a H-bond network
with the other subunit.
(Adapted from Evans et al.,
1981.)
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Figure 10. DNA sequence showing the mutation of Arg-252
to lysine (RK252) and to alanine (RA252) in BsPFK gene.
In vitro mutation was carried out according to Kunkel's
protocol (Kunkel, 1985). Sequencing was performed by
dideoxy chain termination method as described under the
Materials and Methods. WT: wild type
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Figure 11. Subcloninq and expression of BsPFK gene. The
2.5 kb Bspfk fragment was subcloned at the EcoRI-Hindlll
sites of pBR322. The recombinant plasmid was used to
transform E. coli strain DF1020, a pfk deletion mutant.
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SUBCLONING AND EXPRESSION OF BsPFK
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Figure 12. In vitro mutagenesis and subcloninq of Bspfk
mutant into pBR322. (A) Uracil containing single
stranded DNA (lane 2) was annealed to a mutagenic '
synthetic oligonucleotide and the second strand was
synthesized using T4 DNA polymerase (lane 3). Lane 4,
purified RF DNA of M13Bspfk.
(B) pBR322 (lane 2) and
M13Bspfk mutant (lane 3) cut with EcoRI and Hindlll. (C)
Intact pBR322Bspfk (lane 2) and pBR322Bspfk cut with EcoRI
and Hindlll (lane 3) showing the presence of a 2.5 kb
fragment containing the BsPFK gene. Lanes Al and Cl,
lambda DNA cut with EcoRI and Hindlll; lane Bl, lambda DNA
cut with Hindlll. All gels were 0.8 % agarose and the DNA
bands were visualized under UV light after ethidium
bromide staining.
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a promoter recognized by the RNA polymerase in E. coli.
This allows the BsPFK gene to be expressed to high level
in an E. coli system.
High level expression of BsPFK in E. coli and the
thermal stability of this enzyme simplify its
purification.

Heating the extract to 70°C for 15 min

precipitates other E. coli proteins and inactivates the E.
coli PFKA thereby preventing any possible endogenous
contamination if a leak in the mutation of PFK-deficient
host occurs.

The wild type, RK252 and RA252 proteins are

all stable at 70°C for 15 min.

Increased enzyme purity

can be obtained by longer heating in the presence of Fru
6-P.

Fru 6-P, but not Mg-ATP, renders BsPFK more heat

stable.

A higher ionic strength may be used to elute

BsPFK from Cibacron Blue 3GA-Agarose whereas EcPFKA can be
eluted by Mg-ATP from the same column.

The use of a PFK-

def icient host, the thermal lability of EcPFKA and the
differential binding of host and cloned enzymes to the
column guarantee the absence of any EcPFKA contamination.
PFK from Streptococcus lactis (Fordyce et al., 1982) and
yeast (Bohme et al., 1972) are also eluted from Cibacron
Blue column at high ionic strength.

Table 2 summarizes

an example of the procedure employed for the purification
of BsPFK.

The purified wild type, RA252 and RK252 enzymes

are homogeneous as judged by SDS-PAGE (Figure 13) and have
the same relative electrophoretic mobilities.
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Table 2. Sample purification of BsPFK mutant (DA59). The high
specific activity of the crude lysate and low purification fold
imply the high expression of the mutant in the host cell
DF1020.
Volume
(ml)

Sonication 40.0
Heat
Treatment 37.5
Cibacron
Blue
61.5
Glycerol
2.0
Cone'n

Activity
(U/ml)

% Yield

[Protein]
(mg/ml)

Specific Fold
Activity Purif1
(U/mg)

218.1

100

6.56

33.2

161.3

70

2.74

58.9

1.8

59.3

42

0.48

123.5

3.7

671.4

15

5.28

127.2

3.8

Figure 13. Polyacrylamide gel electrophoresis in the
presence of dodecvl sulfate. Lanes 2-4 show the
purification of the wild type; Lanes 6-11, purified
mutants.
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Kinetic Comparison of the Two Mutants and Wild Type
The wild type BsPFK and the two mutants, RK252 and
RA252, follow hyperbolic Michaelis-Menten kinetics with
respect to both substrates (Figures 14 and 15).

Mutation

to lysine (RK252) increases the Km for Fru 6-P from 0.029
to 1.16 mM whereas mutation to alanine (RA252) increases
the Km for Fru 6-P from 0.029 to 41 mM suggesting that the
decreased affinity of RA252 for Fru 6-P is probably due to
a removal of a positive charge essential for binding to
the phosphate group of the substrate.

ATP affinity is not

significantly affected by either mutation (Table 3).

The

assumption of a global conformational transition in the
enzyme explains these data as well as the change in the
affinity for PEP which binds at a site far from the Fru 6P binding site (Evans et al., 1981).
The hyperbolic kinetics with respect to Fru 6-P
concentration is not affected by ATP or NH4+
concentrations.

Cooperativity is observed in the presence

of PEP with Hill numbers of 2.2, 2.4, and 1.7 for wild
type, RK252, and RA252, respectively (Figure 14) at pH 8.2
and PEP concentrations close to their dissociation
constants.
ATP inhibition of the wild type and mutants is
observed at low Fru 6-P concentrations and is reversed by
GDP or high Fru 6-P concentrations (Figures 5, 15C and
16).

The higher sensitivity of RA252 to ATP inhibition

Figure 14. Dependence of BsPFK activity on Fru 6-P
concentration in the absence or presence of an effector.
(A) Wild type, (B) RK252, (C) RA252. •, no effector;o
, 0.5 mM GDP; D , PEP (0.5 mM for wild type, 0.2 mM for
RK252, 5 uM for RA252); A , 0.5 mM GDP + the abovementioned PEP concentrations.
Standard assays described
under the Materials and Methods contained 1 mM ATP (A and
B) and 0.5 mM ATP (C). Relative activities are relative
to the maximal activity of each enzyme form attained in
the absence of an effector.
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Figure 15. Dependence of BsPFK activity on ATP
concentration in the absence or presence of an effector.
Assays described under the Materials and Methods were done
at saturating Fru 6-P concentration: • , no effector; o ,
0.5 mM GDP; □ , with indicated concentration of PEP;
,
0.5 mM GDP + indicated concentration of PEP.
(A) Wild
type, [PEP] = 0.5 mM, [Fru 6-P] = 1 . 0 mM.
(B) RK252,
[PEP] = 0.2 mM, [Fru 6-P] = 25 mM.
(C) RA252, [PEP] =
5.0 uM, [Fru 6-P] = 120 mM. Lineweaver-Burk plots in the
absence ( • ) or presence (o ) of 0.5 mM GDP are shown in
the insets.
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Table 3.
of BsPFK

Effect of Arg-252 mutation on the kinetic parameters

Enzyme Form
Vmax
(umole/min/
mg )
Wild Type
RK252
RA252

219 + 4
43+1
85+9

Km, Fru 6-P
(mM)

Km, ATP
(mM)

K i , GDP
(m M )

0.029+0.002

0.068 +

0.001

0.49 + 0.04

1.16 + 0.04

0.034 +

0.001

0.32 + 0.05

4 1 + 8

0.086 + 0.007

0.26 + 0.05

Figure 16. ATP inhibition of RA252 activity at low Fru 6P concentration. Initial velocities were measured as
described under the Materials and Methods using 25 mM Fru
6-P and the indicated ATP concentrations. The inhibition
observed in the absence of an effector (D ) or in the
presence of 0.5 uM PEP (O) was reversed by addition of
0 .5 mM GDP (•+ ) or 0.5 mM GDP and 0.5 uM PEP (A ) .
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may be due to poor binding of Fru 6-P and/or higher
affinity for ATP at the effector site.

ATP inhibition at

low Fru 6-P concentration has been observed in PFK
preparations from other sources (Simon and Hofer, 1977;
Kotlarz and Buc, 1981; Fordyce et al., 1982; Marschke and
Bernlohr, 1982).

A negative cooperativity between the

binding of ATP and Fru 6-P seems to occur in this enzyme.
For example, the Km of BsPFK for Fru 6-P increases from
0.029 to 0.072 mM when ATP is increased from 1.0 to 7.0 mM
(Figure 17).

This suggests that the binding of one

substrate to the active site can influence the binding of
the second substrate, a relationship not observed in
EcPFKA (Blangy et al.. 1968).
Mutation of Arg-252 to alanine decreases the Vmax
from 219 to 85 umole/min-mg.

RA252 requires greater than

100 mM Fru 6-P for saturation (Figure 14C), reflecting the
complicating effect of high ionic strength rather than
true saturation.

RK252, on the other hand, has a Vmax of

43 umole/min-mg.

The

e -amino group of Lys-252 probably

interacts with Fru 6-P or with an adjacent amino acid
residue which would affect the spatial orientation of the
substrate and the catalytic rate of the enzyme.

Since the

mutation of Arg-252 to alanine did not abolish the enzyme
activity, I surmise that this residue does not participate
directly in the catalytic process.

Figure 17. Effect of ATP concentration on Fru 6-P
affinity for the wild type BsPFK. BsPFK activities were
determined as described under the Materials and Methods
using either 1 mM (o ) or 7 mM (-f ) ATP and the indicated
Fru 6-P concentrations.
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Effects of PEP and GDP
PEP is a potent inhibitor of the wild type BsPFK,
RK252 and RA252.

The dissociation constants of PEP at

saturating concentrations of Fru 6-P and ATP are 0.44,
0.19 and 0.0065 mM, respectively (Figure 18).

Affinity

for PEP increases at high ATP concentrations whereas
negative cooperativity is observed between PEP and Fru 6-P
(Table 4).

The high

explained by a major

sensitivity of RA252 to PEP can be
conformationalchange as a result of

the Arg-252 mutation.
Inhibition by PEP is reversed by GDP (Figure 14).
However, in the absence of PEP, GDP per se competes with
ATP (Figure 15).

ADP exerts a similar effect (Figure 19).

The Ki values for GDP are 0.49, 0.32, and 0.26 mM for the
Wild Type, RK252, and RA252, respectively.

These results

imply that GDP can bind at two separate sites: namely the
effector and the ATP

binding sites.

of BsPFK seems to be

less specific than that of the

EcPFKA.

The ATP binding site

I obtained Km values of 0.068 and 0.156 mM for

ATP and GTP, respectively for BsPFK, whereas EcPFKA has a
comparable affinity for ATP (Km = 0.06 mM) but a 7-fold
less affinity for GTP (Km = 1.2 mM)

(Blangy et al., 1968).

This explains the competitive inhibition of BsPFK by both
ADP and GDP.

On the other hand, ADP, but not GDP, is a

competitive inhibitor of EcPFKA (Blangy et al., 1968).

Figure 18. Effect of Arg-252 mutation on the dissociation
constant of PEP. The enzymes were assayed in the presence
of 1 mM ATP and saturating Fru 6-P concentrations: 1 mM
Fru 6-P for the wild type ( • ), 50 mM Fru 6-P for RK252
( o ), and 120 mM Fru 6-P for RA252 ( A ) . The absolute
value of the X-intercept is equal to the dissociation
constant of PEP (Blangy et al., 1968).
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Table 4. Effect of the concentration of Fru 6-P and ATP on the
PEP dissociation constant of the wild type BsPFK, RK252 and
RA252 mutants
Enzyme Form
Wild Type

RK252

RA25 2

[Fru 6-P], (mM)

[ATP],

(mM)

Kpep,

(mM )

1 .0

1 .0

0 .44

+ 0.02

0 .2

1.0

0. 15

+ 0.02

1 .0

0. 1

9.59

+_ 0.02

50.0

1.0

0 .19

+ 0.05

5.0

1 .0

0.03

+ 0.01

50 .0

0. 1

0 .30

+ 0 .04

120.0

1 .0

0.0065

+ 0.0008

50.0

1 .0

0.0047

+ 0.0006

120.0

0.1

0.047

+ 0.002

Figure 19. Inhibition of wild type BsPFK activity by ADP.
Activities were measured using 1 mM Fru 6-P, the indicated
concentrations of ADP and various ATP concentrations: □, 1
mM ATP; +, 1.58 mM ATP; and O , 3.2 mM ATP.
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Discussion
The data presented in this study support a central
role for Arg-252 in the substrate binding site through
maintenance of subunit orientation (Figure 9).

Mutation

of Arg-252 to lysine results in a moderate decrease in the
affinity of the enzyme for Fru 6-P while substitution with
alanine which has a smaller, uncharged side chain causes a
much more drastic fall in affinity (Table 3).

The

observed changes in Km further suggest that Arg-252 plays
a role in R to T transition based upon comparison with
previously reported Km changes for EcPFKA during
transition (0.0125 to 25 mM)

(Blangy et al., 1968)).

Concomitant analysis of PEP binding reveals that the
dissociation constants for PEP decrease in the two mutants
studied (Table 4).

The more moderate decrease observed in

the lysine mutant suggests that its long, positively
charged side chain meets the minimal requirements for
holding the subunits in the wild-type structure.

The

importance of a single amino acid residue in the
maintenance of quaternary structure is revealed by the
dramatic fall in the dissociation constant for PEP seen in
the alanine mutant.

Since PEP affinity is increased in

the T state (Blangy et al., 1968), results with the
alanine mutant further support the R to T transition
model.

CHAPTER V
MUTATION OF ARG-25, ARG-211 AND ASP-59
Mutation, Expression and Purification
Arg-25, Arg-211 and Asp-59 have been proposed to be
involved in the binding of ADP and PEP (Table 1 and Figure
20).

The positively-charged side chain of the first two

amino acid residues interact with negatively-charged
phosphate group(s) of the effectors.

If Asp-59 interacts

with the same group, it is probably mediated by Mg2+.
These residues have been mutated to Ala.
been mutated to methionine.

Asp-59 has also

I designate Arg-25 ** Ala as

RA25, Arg-211 -*■ Ala as RA211, Asp-59 -> Ala as DA59 and
Asp-59

Met as DM59.

Figure 21 shows the nucleotide

sequences for the four mutants.

Similar to the wild type,

these mutants are all stable at 70°C for 15 min and have
the same relative electrophoretic mobility in SDS-PAGE
(Figure 13).

Effects of Fru 6-P and ATP Concentration on BsPFK Activity
The wild type BsPFK and the mutants, except RA25,
follow hyperbolic Michaelis-Menten kinetics with respect
to Fru 6-P and ATP (Figures 22 and 23) and exhibit the
same affinity for these substrates.

RA25 exhibits the

same hyperbolic profile with respect to ATP but it shows a
slight sigmoidicity with respect to Fru 6-P concentration

102
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Figure 20. BsPFK effector site. ADP is bound between two
subunits shown by the solid and open bonds. (Adapted from
Evans et al., 1981.)

RRG154

HIS215

THR158

105

Figure 21. DNA sequence showing the mutations of Arg-25,
Arg-211, and Asp-59. In vitro mutation was carried out
according to Kunkel's protocol (Kunkel, 1985). Sequencing
was performed by dideoxy chain termination method as
described under the Materials and Methods. WT, wild type;
RA25, Arg-25 + Ala; RA211, Arg-211
Ala; DA59, Asp-59
Ala; DM59, Asp-59
Met.
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Figure 22. Dependence of BsPFK mutant activity on Fru 6-P
concentration in the absence or presence of an effector.
All assays contained 1 mM ATP and the indicated Fru 6-P
concentrations.
(A) RA25, (B) RA211, (C) DA59, (D) DM59.
D , no effector; *t, 0.5 mM GDP;
0.5 mM PEP; A , 0.5 mM
GDP + 0.5 mM PEP.
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Figure 23. Dependence of BsPFK mutant activity on ATP
concentration in the absence or presence of an effector
All assays contained 1 mM Fru 6-P and the indicated ATP
concentration.
(A) RA25, (B) RA211, (C) DA59, (D) DM59
□ , no effector; +,0.5 mM GDP;
0.5 mM PEP; A , 0.5
GDP + 0.5 mM PEP.
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(Figure 24).

Its affinity for Fru 6-P is half of the wild

type and the other mutants and it has a Hill number of 2.0
which implies the presence of cooperativity as far as Fru
6-P binding is concerned.

Effects of PEP and GDP on Mutants and Wild Type Activity
PEP is a potent inhibitor of the wild type BsPFK.
Mutation of Asp-59 to alanine or methionine renders BsPFK
slightly more sensitive to PEP inhibition (Figure 25).
The dissociation constants of PEP are 0.44, 0.42 and 0.16
mM for wild type, DA59 and DM59, respectively (Table 5).
GDP and high Fru 6-P concentrations reverse the inhibition
by PEP (Figure 22).
RA25 and RA211 exhibit 100-fold less sensitivity to
PEP than does the wild type (Table 5 and Figure 25).

No

sigmoidicity is observed with respect to Fru 6-P in the
presence of the inhibitor.

Addition of GDP does not

affect the kinetic profile of these two mutants (Figures
22 and 23).

Discussion
Previous kinetic studies (Chapter III, this
dissertation) have shown that the wild type BsPFK is
allosterically different from the major E. coli PFK.

The

former exhibits a hyperbolic curve with respect to Fru 6-P
whereas the latter shows sigmoidal behavior.

Mutation of

Figure 24. Comparison of the effect of Fru 6-P
concentration on the activity of the wild type BsPFK and
the four mutants. Activities were measured as described
under the Materials and Methods using 1 mM ATP and the
indicated concentrations of Fru 6-P. o, wild type; O,
RA25; V , RA211; Q , DA59; A , DM59.
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Table 5.

Kinetic parameters of the mutants and wild type BsPFK

Enzyme Form

Km, Fru 6-P
(mM)

Kpep,

(m M )

Wild Type

0.029

+ 0.002

0.44

+ 0.02

RA25

0.06

+ 0.01

45

+9

RA211

0.029

+ 0.003

50

+ 10

DA59

0.027

+ 0.003

0.42

+ 0.07

DM59

0.028

+ 0.003

0.16

+ 0.02
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Figure 25. Effect of PEP concentrations on the activity
of BsPFK. Activities were measured as described under the
Materials and Methods in the presence of 1 mM ATP, 1 mM
Fru 6-P and indicated concentrations of PEP in the absence
(open marks) or presence (closed marks) of 0.5 mM GDP.
(A) Wild type, with ( • ) and without (o ) GDP; DA59, with
( ■ ) and without ( □ ) GDP; DM59, with (▲ ) and without
( A ) GDP.
(B) RA25, with (♦) and without (O) GDP;
RA211, with ( V ) and without ( V ) GDP.

B

c 0.8

I

0 4

10

0.4

0.6

0.8
[P E P ], mM

15

20

123

Arg-25 to Ala, a residue at the regulatory site, causes a
dramatic change in the degree of cooperativity between the
subunits of BsPFK.

This mutation probably causes amino

acid residues at the regulatory site to orient themselves
in a conformation similar to that they assume in the
presence of PEP.

Addition of PEP to RA25 does not

increase the cooperativity due to poor binding of the
inhibitor.

Change in cooperativity between subunits has

also been reported in E. coli aspartate transcarbamoylase
by mutation of single amino acid residue (Eisenstein et
al., 1988).
X-Ray structure of BsPFK shows that Arg-25 binds to
the a- and 8-phosphates of ADP or GDP and Arg-211 binds to
the a-phosphate and adenine group of ADP or GDP (Figure
20)

(Hellinga and Evans, 1985).

The low sensitivity to

PEP inhibition and the inability of GDP to reverse this
effect prove unequivocally that Arg-25 and Arg-211 are
involved in the binding of both modulators.

This suggests

that the positively charged guanidinium moiety of arginine
interacts with the negatively charged phosphate group (s)
of ADP, GDP or PEP and a metal ion is not needed in this
interaction.
Results on PEP and GDP binding of the two Asp-59
mutants suggest that the side chain of this amino acid
residue is not directly involved in the binding of these
modulators.

This is consistent with the X-ray structure

of BsPFK which shows that the polypeptide part of Asp-59,
but not its side chain, binds to the 3-phosphate of ADP or
GDP (Figure 20)

(Hellinga and Evans, 1985).

This is

logical in terms of very poor electrostatic interaction
between two negatively charged groups (i. e. carboxyl of
Asp and phosphate of ADP or PEP) unless a metal ion
bridges them. The 3-fold sensitivity of DM59 to PEP
inhibition compared to the wild type can not be explained
in terms of the nature of the side chain.

However, it is

important to note that Asp-59 is replaced by methionine in
the homologous rabbit muscle PFK and modification of this
residue does not affect the properties of the eucaryotic
enzyme (Latshaw et al., 1987).
The above-mentioned mutations define the role of Arg25, Arg-211 and Asp-59 in BsPFK.

Other mutations have to

be conducted to gain more information on the mechanism of
regulation of BsPFK and the interaction between its
subunits.

CHAPTER VI
MOLECULAR CLONING AND SEQUENCING OF A PARTIAL HUMAN MUSCLE
FRUCTOSE 6-PHOSPHATE-1-KINASE GENE

Cloning and Sequencing of HMPFK Gene
Lambda phage plaques containing human DNA inserts
were screened for the PFK gnes with a nick-translated
M13mpl8 bacteriophage RF DNA containing the 5' region
fragment of RMPFK gene (corresponding to the N-terminal
region of the enzyme) as hybridization probe.

Only one

positive plaque gave a reproducible signal on duplicate
filters (Figure 26A).

This plaque was further purified by

replating (Figure 26B).

DNA from the purified phage clone

was characterized by digestions with several restriction
endonucleases followed by nitrocellulose blot
hybridization with a nick-translated phage RF DNA
containing the 5' region of RMPFK gene (Figure 27A) or an
end-labeled oligonucleotide complementary to codons No. 3
to 9 in the first exon of rabbit PFK gene (Figure 27B) as
probes.

The restriction map is shown in Figure 28.

The

2.8 kb EcoRI/Hindlll fragment was subcloned in M13mpl8 and
M13mpl9 phage vectors.

M13 phage plaques were then

selected for the PFK insert by their

p-galactosidase

phenotype and by dot blot hybridization.

Single-stranded

phage DNA from these M13 phage clones were purified and
used as templates for DNA sequence analysis.
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Figure 26. Purification of human PFK gene cloned in
lambda EMBL4 phage DNA. Human liver DNA was partially
digested with Mbol endonuclease, size fractionated by
sucrose centrifugation and ligated into the BamHI site of
the vector. Phage (at a titer of 300,000 pfu) were seeded
with NM539 E. coli cells on 10 LB agarose plates (150 mm).
Nitrocellulose filters in duplicate were lifted from each
plate and hybridized with nick-translated 5' fragment of
rabbit PFK gene. A positive plaque shown to have
reproducible pattern in duplicated filters (A) was
isolated and further purified by replating (B).
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Figure 27. Nitrocellulose blot hybridization of human PFK
gene fragments. Purified lambda EMBL4 phage DNA
containing human PFK genomic insert was digested by EcoRI
(E), HindiII (H), and SstI (S) endonucleases singly or in
combination. Fragments produced were separated by
electrophoresis on an 0 .8 % agarose gel, blotted onto
nitrocellulose filters and hybridized with nick-translated
M13mpl8 RF DNA containing the 5' region of rabbit PFK gene
(A) or end-labeled synthetic oligonucleotide corresponding
to codons No. 3 to 9 of RMPFK (B). The size markers (M)
are EcoRI and HindiII-digested lambda phage DNA.
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Figure 28. Restriction map of the upstream region of the
HMPFK gene. The insert at the BamHI site of EMBL4 is 13.7
kb. The approximate position of the first exon is shown
by the box. E, EcoRI; H, Hindlll; B, BamHI
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used in these analyses were M13 universal primer and
synthetic oligonucleotides corresponding to codons 3 to 9
or complementary to codons 23 to 28 (PFK1 and PFKhl,
Appendix 6 ).

Total sequence of approximately 400 bp in

the 5' region of the HMPFK gene has been determined.
Figure 2 9 shows this sequence aligned with the
corresponding region of RMPFK gene.

Discussion
A partial sequence of the 5' region and exon I of the
HMPFK gene is shown in Figure 29.

Comparison of the

sequence data with that reported for a HMPFK cDNA
(Nakajima et al., 1987) shows a perfect match in the first
exon and the presence of an additional intron extending
from nt -97 to -9 upstream of the ATG start codon
(downward arrows in Figure 29).

The sequence of the

splice junction agrees with the consensus sequences
including CTGAC (nt -31 to -27) as a possible branch point
(Breathnack and Chambon, 1981).

The 5' end of the intron

has slightly lower homology (67%) with the consensus
sequence; the same degree of homology exhibited by 8 out
of 22 introns in the rabbit muscle PFK gene (Lee et al.,
1987) .

These comparisons suggest that the region is an

active intron.

The presence of intron in the 5'

nontranslated region has been reported in actin genes of
Drosophila (dma2), chicken skeletal muscle, rat skeletal

Figure 29. Alignment of amino acid sequences and DNA
sequences of human (HMPFK) and rabbit (RMPFK) PFK genes in
the first exon region. Capital letters are nucleotide in
the first exon. Flanking regions and introns are printed
in lower case letters. Boldface letters are positions of
base substitution and amino acid replacement. Downward
arrows point to the splice junction. The short sequence
on top is the leading sequence of the HMPFK cDNA.
Sequences in the nontranslated region identical to the
HMPFK cDNA are underlined.
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Leading sequence of hmpfk cDNA: gcctgactgagagtggatcATG-

hmpfk

ctcattctat tcagtcaact ctcttttccc tgaccttagt ttattcccca

hmpfk

aataggttcc aattggggtg ggagggatca gggaggaatt aggaccttag

hmpfk

tagtcttggg cttgattaca tgacatttca gcttgtcagt ctacaagggt

hmpfk
hmpfk

gtggctttcc tctggaagaa gtccaaagct ctcaggctgc aaagctcaga
4cttggtatag tqqqaqaqcc tqactqaqqt ggctctagcc agtctaattg

hmpfk
rmpfk

ccgttccttt agctagtggc atcttgattc ctgctgtgtc ttaactgacc
-gctagcggc accttgacc cagctg tc ctaactgacc

hmpfk
rmpfk

attgtcttaa attctaqaqt qqatc ATG ACC CAT GAA GAG CAC CAT
atcgtcttgc cttctagagt ggatc ATG ACC CAT GAA GAG CAC CAT

hmpfk
rmpfk

GCA GCC AAA ACC CTG GGG ATT GGC AAA GCC ATT GCT GTC TTA
GCA GCC AGA ACC CTG GGG GTC GGC AAG GCC ATC GCG GTG CTC

hmpfk
rmpfk

ACC TCT GGT GGA GAT GCC CAA Ggt aaggaggagg-ACC TCC GGC GGA GAT GCC CAA Ggt aaggaggagg—
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muscle and rat cytoplasm ( $-actin)
Ordahl and Cooper, 1983).

(Zakut et al., 1982;

An upstream intron in rat

collagen II gene has been reported to contain an enhancer
element which controls the cell-specific expression of the
gene (Horton et al., 1987); hence it is possible that the
identified upstream intron in HMPFK gene may have the same
function.
The comparison presented in Figure 29 reveals strong
sequence conservation between human and rabbit PFK genes.
Although only a short (62 bp) sequence upstream of the ATG
codon of the RMPFK gene is available, this flanking region
is highly homologous to that of the HMPFK gene.

This

short sequence contains both the 3' splicing junction and
the branch sequence of an intron.

The whole upstream

intron described for the HMPFK gene may also exist in the
RMPFK gene based on the 8 9% nucleotide homology in the
coding region of the two genes.
The first exons of the RMPFK and HMPFK genes are
identical in length (both 87 bp or 29 amino acids) and
homologous in sequence.

Among the 11 sites of

substitutions, eight are silent.

Three substitutions

resulted in two highly conservative amino acid
replacements, a Lys -> Arg at position 9 and an lie -*■ Val
at position 13.

Surprisingly, except for one C -*■ G

transversion, all other base substitution positions are
A's and T's in HMPFK gene and G's and C's in the rabbit
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gene.
In the nontranslated region, alignment of the
homologous sequences shows that in rabbit PFK gene, two
deletions (one and two bp) bracket a six bp region which
constitutes a PvuII site in the rabbit gene.

A -*■ T

transversion erases this restriction site in the human
gene.

Eight other base substitutions are identified in

this nontranslated region; again they are A's and T's in
the human gene and G's and C's in the rabbit gene.

In

comparing the rest of the human muscle PFK cDNA sequence
(Nakajima et al., 1987) and the rabbit muscle PFK gene
(Lee et al., 1987) the data show a significant bias for
A's and T's in the HMPFK gene and G's and C's in the
rabbit gene.

Of the 256 nucleotide substitutions

identified, 71% are A's and T's in the human cDNA and C's
and G's in the rabbit gene.

The evolutionary selection

pressures which cause this bias are not known but it is
interesting to note that this finding is consistent with a
survey of 13 rabbit coding sequences which showed that G's
and C's are strongly favored in the third position of
degenerate codons (Putney et a l ., 1983).

However, this

observation does not agree with the comparison of
sequences of human and rabbit

8 -globin

genes where no

such bias has been detected (Kafatos et al., 1977).

CHAPTER VII
SUMMARY

The results reported in this dissertation show the
difference in the kinetic behavior of BsPFK and EcPFKA
which have been previously reported to have similar
properties.

BsPFK exhibits a hyperbolic Michaelis-Menten

kinetics with respect to Fru 6 -P while EcPFKA shows a
sigmoidal profile.
This dissertation also illustrates that BsPFK is a
good system to study the relationships between structure
and function in PFK by site-directed mutagenesis.

Kinetic

data are presented to show that mutation of Arg-252 to Ala
converts BsPFK to its allosterically inhibited
conformation (tight or T form).

Truncation of Arg-25 and

Arg-211 to Ala makes the enzyme insensitive to its
inhibitor phosphoenolpyruvate.

Mutation of Asp-59 to

either Ala or Met seems not to significantly affect the
regulation of BsPFK.

The results obtained in this

procaryotic enzyme may have relevance in the understanding
of the homologous but more complex eucaryotic PFK.
In summary, site-directed mutagenesis of putative
critical amino acid residues is an excellent tool for the
investigation of enzymological phenomena like R to T
transition and modulator binding in allosteric enzymes.
This tool will facilitate-future research on the molecular
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basis of enzyme regulation especially PFK, the key
regulatory enzyme of the glycolytic pathway.
The last part of this dissertation is an initial
attempt in the characterization of the 5' nontranslated
region of the HMPFK gene.

An intron upstream of the ATG

initiation codon has been identified.

This probably plays

an important role in the tissue-specific expression of
this gene.

CHAPTER VIII
FUTURE DIRECTIONS
The results presented in this dissertation provide
the initial set of data for a more complete understanding
of the relationship of structure and function in BsPFK.
Prior to subsequent mutations, a thorough comparison in
the kinetic behavior of the wild type EcPFKA and BsPFK,
which is not available in the literature, may be
investigated.

The enzymology of EcPFKA has been

thoroughly studied unlike BsPFK.

However, the X-ray

structure of BsPFK is known but not that of EcPFKA; hence
literature explains kinetic data of EcPFKA using the known
structural details in BsPFK.

The availability of the

cloned EcPFKA and BsPFK will facilitate the investigation
of the differences and similarities in these two
procaryotic enzymes previously assumed to be similar.
The order of ligand binding (substrates and
products), anomeric specificity and NH4+-dependent
mechanism of catalysis may be investigated similar to what
have been reported in other systems (Simon and Hofer,
1978; Younathan et al., 1981; Abrahams and Younathan,
1971) .
Conclusions presented in this dissertation on Arg-252
mutations are all based on kinetic data.

The R to T

transition model may be ultimately tested by determining
the X-ray structure of RA252 and comparing it with the
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known 3-dimensional structure of the wild type.
Further investigation on cooperative interactions may
be conducted by more mutations at the Fru 6 -P binding
site.

Truncation of amino acid residues at this site like

Asn-12, Thr-156, Arg-162, Arg-243 and His-160 may be
helpful in the investigation of homotropic cooperativity.
Similar to Arg-252, these residues have been proposed to
be involved in Fru 6 -P binding and/or subunit interaction.
The existing Arg-252 mutants may be tested for sugar
specificities.
PFKs.

Fru 1-P is a poor substrate of procaryotic

Its rate of phosphorylation may be studied using

the Arg-252 mutants.

Fru 2-P may be tested similarly.

The sigmoidal behavior of RA25 mutant provides an
insight into the cooperative interaction between subunits.
Mutations of other amino acid residues at the effector
site may increase the heterotropic cooperativity.
Simultaneous multiple mutations at this site may convert
BsPFK to a form with properties similar to EcPFKA, i.e.
sigmoidal kinetics with respect to Fru 6 -P.

One

interesting residue is Gly-55 in BsPFK (Tyr in EcPFKA)
which may be mutated to Tyr.

Tyr-55 in EcPFKA has been

proposed to bind with ADP (Lau et a l ., 1987).

Moreover,

the negatively-charged side chain of Asp-59 may be changed
to Arg.

This may enhance the binding of the modulators.

By systematic mutations of all the residues at the
effector site and by careful classification of the effects
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that these changes may bring about, one might be able to
discover mutations which interchange the properties of the
modulators: ADP and GDP may become inhibitors, and PEP an
activator.
To clearly understand how the effector site
functions, PEP (a very effective inhibitor),
phosphoglycolate (less effective inhibitor) and 2 phosphoglycerate (similar in structure to PEP but not an
inhibitor) affinities may be investigated using the
existing and the future mutants.
Mutants which have been expressed and purified but
remain to be characterized are RA154, WA17 9 and WF179.
The mutation of the sole Trp residue in BsPFK may be
important for some fluorometric analyses.
The isolated 5' flanking region of the human muscle
PFK gene needs further characterization.
Cap site remain to be located.

The TATA box and

Identification of possible

enhancer(s) in this region and isolation of any trans
acting factor involved in transcription of this gene is a
very promising project.

ABBREVIATIONS
A

- Adenine

ADP

- Adenosine diphosphate

AMP

- Adenosine monophosphate

ATP

- Adenosine triphosphate

bp

- Base pair(s)

BSA

- Bovine serum albumin

BsPFK

- Bacillus stearothermophilus PFK

C

- Cytosine

cAMP

- 3',5'-cyclic AMP

cDNA

- Complementary DNA (transcribed or copied
from mRNA)

C-type PFK

- Brain isozyme of PFK

DA59

- Asp-59 to Ala mutant

DM59

- Asp-59 to Met mutant

DMSO

- Dimethylsulfoxide

DMT

- Dimethyltrityl

DTT

- Dithiothreitol

EcPFK

- Escherichia coli PFK

EcPFKA

- Major EcPFK

EcPFKB

- Minor EcPFK

EDTA

- Ethylenediaminetetraacetic acid

Fru 1,6-P2

- Fructose 1, 6 -bisphosphate

Fru 2,6-P2

- Fructose 2, 6 -bisphosphate

Fru 6 -P

- Fructose 6 -phosphate

G

- Guanine

142

GDP

-

Guanosine diphosphate

Glu 1,6-P2 -

Glucose 1, 6 -bisphosphate

GTP

-

Guanosine triphosphate

HEPES

-

N-2-Hydroxyethyl piperazine-N'-2-ethane
sulfonic acid

HMPFK

-

Human muscle PFK

HMpfk

-

Gene coding for HMPFK

IPTG

- Isopropyl-$ -D-thiogalactopyranoside

hr

-

hour(s)

kb

-

Kilobase pairs

Km

-

Michaelis constant

L-type PFK -

Liver isozyme of PFK

mA

milliampere(s)

-

M-type PFK -

Muscle isozyme of PFK

Man 1,6-P2 -

Mannose 1,6 -bisphosphate

min

minute(s)

-

NAD

- Nicotinamide adenine dinucleotide

NADH2

- Nicotinamide adenine dinucleotide (reduced)

nt

-

nucleotide(s)

OD

-

Optical density

PAGE

- Polyacrylamide gel electrophoresis

PEG

-

Polyethyleneglycol

PEP

-

Phosphoenolpyruvate

PFK

-

6-Phosphofructo-l-kinase

Pi

-

Inorganic phosphate

PMSF

-

Phenylmethylsulfonyl fluoride

RA25

- Arg-25 to Ala mutant

RA252

- Arg-252 to Ala mutant

RF

- Replicative form

RK252

- Arg-252 to Lys mutant

RMPFK

- Rabbit muscle PFK

RMpfk

- Gene coding for RMPFK

SDS

- Sodium dodecylsulfate

T

- Thymine

TCA

- Tricarboxylic acid cycle

TEAB

- Triethylamine buffer

TEMED

- N, N, N', N'-tetramethylethylenediamine

TLC

- Thin layer chromatography

TrisCl

- Tris(hydroxymethyl)aminomethane chloride

Vmax

- Maximum velocity

X-gal

- 5-Bromo-4-chloro-3-indolyl- $ -D-galactoside

Appendix 1
Procedure provided by BRL for transformation of subcloning
efficiency E . coli DH5a competent cells with some
modifications:
1.

Mix 20 ul competent cells with 1 ul ligation reaction

by moving pipette through cells while dispensing.
2. Incubate on ice for 30
3. Heat shock at 37°C

minutes.

for 20 seconds.

4.

Place microfuge tube on ice.

5.

Add 0.95 ml of LB.

6.

Shake at 225 rpm for 1 hr at 37°C.

7.

Concentrate cells by microcentrifuging for 5 seconds

and resuspend in 110 ul LB.
8.

Plate 90 ul, 10 ul

ug/ml ampicillin.

Add

and 1 ul on LB platescontaining 50
100 ul LB to the 10 ul and 1 ul

volumes for spreading.
9.

Incubate overnight at 37°C.
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Appendix 2
Preparation of DF1020 Competent Cells (Hanahan, 1983)
1.

Inoculate 50 ml SOB medium in 500 ml Erlenmeyer flask

with 5 overnight-grown colonies of DF1020.
2.

Incubate at 37°C until the cell density is 6-9 X 107

cells/ml.
3.

Pellet the cells by centrifugation at 750

for 12 - 15

- 1,000 X g

min at 4°C and drain the pelleted cells

thoroughly.
4.

Resuspend the cells in 16 ml frozen storage buffer

(FSB, preparation described below) by vortexing
moderately.

Incubate on ice for 10-15 min.

5.

Pellet the cells as before,

and drain thoroughly.

6.

Resuspend the cells in 4 ml FSB.

7.

Squirt 145 ul DMSO into the

center of the cell

suspension and immediately swirl the tube for 5 - 1 0

sec.

Incubate on ice for 5 min.
8.

Add 145

ul DMSO as before and incubate on ice for 10-

15 min.
9.

Pipette 200 ul aliquots into chilled 1.5 ml

microcentrifuge tube and flash freeze in a dry ice/ethanol
bath for several min.
10.

Store at -70°C.

Preparation of frozen storage buffer (FSB):
Compound
KC1

Amount/liter
7.4 g

Final Concentration
100 m M
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MnCl 2 .4H20

8.9 g

45 mM

CaCl2 .2H20

1.5 g

10 mM

HACoC13

0.8 g

Potassium acetate

10 ml of 1 M
stock (pH 7.5)

Glycerol (pH

3 mM

6.2) 100 g

10 mM
10 % (w/v)

Adjust a 1 M solution of potassium acetate to pH 7.5 using
KOH, then sterilize by filtration through a 0.22 urn
membrane and store frozen.

Prepare a 10 mM potassium

acetate, 10 % glycerol solution using this stock and
purest available water.

Add the salts as solids, and

adjust the pH to 6.4 using 0.1 N HC1.
pH upward with base.

Do not adjust the

(The pH will drift for 1-2 days

before settling at 6 .1-6.2.)

Sterilize the solution by

filtration through a pre-rinsed 0.22 urn filter, and store
at 4°C.
Preparation of SOB Medium:
Per liter:
Bacto-tryptone
Yeast extract
NaCl

20 g
5g
0.5 g

Adjust to pH 7.5 with potassium hydroxide and
sterilize by autoclaving.

Just before use, add 20 ml of

1 M MgS04, sterilized separately by autoclaving.

Appendix 3
Procedure provided by BRL for transformation of E . coli
DH5aF' competent cells with minor modifications.
1.

Mix 30 ul competent cells with 1 ul diluted ligation

reaction into chilled Eppendorf tube by moving pipette
through cells while dispensing.
2.

Incubate on ice for 30 min.

3.

Heat shock for 45 sec in a 42°C water bath (do not

shake).
4.

Plate tube on ice for 2 min.

5.

Add competent cells to 3.0 ml YT top agar containing

100 ul lawn cells, 50 ul 2 % X-gal and 10 ul 100 mM
isopropyl-B-D-thiogalactopyranoside (IPTG).

X-gal and

IPTG are added just before use.
6.

Pour on YT plate and spread gently.

7.

Allow top agar to solidify at room temperature and

incubate the plates overnight at 37°C.
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Appendix 4
DNA Sequencing Using Sequenase Kit (USBC)
This is a protocol provided by the supplier with minor
modifications.
A.

Sequencing Reactions and Gel Electrophoresis
(I used color coded tubes, i.e. A:blue, C:green,
Grwhite, T:yellow.)

1.

In an Eppendorf tube combine 1 ul primer (2.5 ng/ul),

2 ul sequencing buffer and 7 ul template DNA
(approximately 1 ug).
2.

Warm the capped tube to 65°C for 30 min.

3.

Place the tube at room temperature on the bench for 10

min.
4.

Place 2.5 ul of the ddGTP termination mix in a tube

labeled G.

With a fresh tip for each, fill A, T and C

tubes with 2.5 ul of the ddATP, ddTTP and ddCTP
termination mixes respectively.

Cap the tubes and prewarm

at 37°C for 1 min.
5.

To the annealing mix (step 3) add 1 ul of 0.1 M DTT, 2

ul of 5-fold diluted labeling mix, 0.5 ul [a-35s ] thio-dATP
(10 uCi/ul, 10 uM) and 2 ul of Sequenase diluted 1:8 in
ice-cold TE.

Mix thoroughly with a pipet and incubate at

room temperature for 5-10 min.
6.

When the labeling incubation is complete, remove and

transfer 3.5 ul to each labeled tube in step 4.

Mix

content of each tube, centrifuge and continue incubation
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at 37°C for at least 5 min.
7.

Add 4 ul stop solution to each tube.

8.

Heat the samples to 75-80°C for 2 min and load

immediately on the gel 2-3 ul in each lane.

Use shark-

tooth comb from BRL.
9.

The gel should be pre-run with a power of not more

than 60 watts for 15 min before loading the samples.

Run

the gel with samples using the same condition until the
fast moving dye reaches the bottom of the gel.
10. After running, soak the gel in 10 % acetic acid/10 %
methanol for 30 min
paper.

Dry

and transfer onto a 3 MM Whatman

at 80°C under vacuum for 1 hr.

11. Expose the gel at room temperature with a direct
contact between the Kodak film and the gel for 18 hrs or
longer.
B.

Preparation of the Gel

1.

Prepare 40 % acrylamide solution by mixing 38.0 g

acrylamide, 2.0 g N',N'-methylenebisacrylamide and dH20 in
a total volume of 100 ml.

Stir gently with 2.0 g mixed

bed resin (Amberlite MB1) for at least 30 min.
through a Buchner funnel.

Filter

The filtrate may be stored in a

brown bottle at 4°C.
2.

Prepare

acrylamide,

6

% gel mix in 0.5X TBE by mixing 37.5 ml 40 %

12.5 ml 10X TBE and 115 g urea.

total volume to 250 ml with H 20.
membrane.

Make the

Pass through 0.45 urn

Keep at 4°C in a brown bottle.
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3.

Degas 75 ml 6 % gel mix/O.5X TBE for 15 min at room

temperature.

Transfer on a beaker and while stirring add

150 ul of 25 % ammonium persulfate and 30 ul TEMED.
4.

Pour the gel mix between two glass plates using 0.2

or 0.4 mm thick spacers.

The shorter glass plate should

be siliconized.
5.

Let it polymerize for 2 hrs.

C.

Contents of USBC Sequenase Kit

1.

5X sequenase buffer (200 mM Tris-Cl, pH 7.5, 50 mM

MgCl2, 250 mM NaCl) .
2.

Control DNA M13mpl8

(0.2 ug/ul)

3.

Universal primer (0.5 pmol/ul)

4.

0.1 M DTT

5.

5X dGTP labeling mix (7.5 uM dGTP, 7.5 uM dCTP, 7.5 uM

dTTP)
6.

5X dITP Labeling mix (15 uM dITP, 7.5 uM dCTP, 7.5 uM

dTTP)
7.

ddG termination mix for dGTP (80 uM dGTP, 80 uM dATP,

80 uM dCTP, 80 uM dTTP, 8 uM ddGTP)
8.
8

9.

ddA termination mix for dGTP (same as in # 7 but with

uM ddATP instead of ddGTP)
ddT termination mix for dGTP (as # 7 but with 8 uM

ddTTP instead of ddGTP)
10. ddC termination mix for dGTP (as # 7 but with 8 uM
ddCTP instead of ddGTP)
11. ddG termination mix for dITP (160 uM dITP, 80 uM dATP,

80 uM dCTP, 80 uM dTTP,

1 .6 uM ddGTP)

12. ddA termination mix for dITP (as in # 11with

8

uM

ddATP instead of ddGTP)
13. ddT termination mix for dITP (as in # 11 with 8 uM
ddTTP instead of ddGTP)
14. ddC termination mix for dITP (as in # 11 with 8 uM
ddCTP instead of ddGTP)
15. Sequenase enzyme
16. Stop solution (95 % Formamide, 20mM EDTA, 0.05%
Bromophenol Blue, 0.05% Xylene Cyanol FF).
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Appendix 5
Plaque Hybridization and Screening With
Tetramethylammonium Chloride Wash (S. Lee, personal
communication)
1.

Chill plates with 100-200 plaques for 10-30 min at

4°C.
2.

Lay flat a dry nitrocellulose filter onto the agar and

let the phage be adsorbed for 5 min.
3.

Orient the filter by stabbing an inked needle through

the filter.
4.

Peel carefully the filter off; avoid pulling agar

5.

Air dry the filter

for 5 min on a sheet of 3

off.
MM

Whatman filter paper.
6.

Make duplicate filter by repeating steps 2-5 with a

fresh nitrocellulose filter.
7.

Wet a sheet of Whatman paper with 0.5 N NaOH/1.5 M

NaCl draining off the excess liquid by rolling a glass
rod.
8.

Place the nitrocellulose filters onto the paper,

plaques up, for 5 min.
9.

Transfer with forceps to a sheet of dry Whatman paper

and let them air dry for 2-3 min.
10.

Repeat steps 8 and

9.

11.

Place filters onto a sheet of Whatman paper soaked

with 1 M Tris-Cl (pH 8.0) for 5 min.
12. Remove the filters and air dry for 2-3 min.
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13. Repeat steps 11-12.
14. Place filters onto a sheet of Whatman soaked with 1 M
Tris-Cl (pH 8.0)/l.5 M NaCl for 5 min.
15. Transfer the nitrocellulose filters into 100 ml 6X SSC
for 2 min.
16. Remove and air dry for 10 min.
17. Bake the filters at 80°C under vacuum for 1 hr.
18. Place the filters into clean petri dish, plaques up,
containing prehybridization solution (6 X SSC, 10X
Denhardt's solution, 0.1% SDS) enough to cover the
filters.
19. Cover and incubate at 37°C for 1 hr with gentle
shaking.
20. Replace prehybridization solution with hybridization
solution (6X SSC, 10X Denhardt's solution, 106 - 107 cpm
probe).
21. Incubate at room temperature overnight with gentle
shaking.
22. Transfer the filters into 100 ml 6X
1

SSC and swirl for

min at room temperature.

23. Replace 6X

SSC with a fresh solution and swirl for 5

min.
24. Repeat washing until the Geiger counter does not
detect counts in the wash.
25. Briefly blot onto 3 MM Whatman paper then wrap filters
in Saran Wrap.

Do not let the filters to air dry.
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26. Autoradiograph for 3 hrs with intensifying screen at
-70°C.
27. Wash the filters at higher temperature to select the
mutant.

Wash in 3 M tetramethylammonium chloride

((Me)4NCl) at room temperature for 2-3 min.
29. Transfer in 100 ml 3 M (Me)4NCl preheated at the
desired washing temperature.

(Approximate washing

temperature for 16-mer: 49-50°C; for 25-mer, 64-65°C.)
Wash 10-15 min in a shaker water bath.
30. Remove the filters and check the signal with aGeiger
counter.

If the signal is reasonably high,

increase the

washing temperature by 2°C and wash them again.
31. Blot dry the filters, cover with Saran Wrap and
autoradiograph with intensifying screen at -70°C.

The

duration of exposure depends on the intensity of the
count.

156

Appendix 6
Synthetic oligonucleotides used as primers for in vitro
mutation and DNA sequencing.
Code

Sequence (5' - 3')

Start Position* Strand** Remarks
(nt)

BsPFK2
BSPFK3
BSPFK4
BSPRI5
BsPRI 6
BsPRI7
BsPRI 8
BsPRI9
BsPRlO
BsPRI1
BsPR12
Bs252M

GCGGAACACAACAGCG
CGGGTTTGACACGGCGC
GGCGACCGTTCGGCCCG
ATCCCCGACATCGCCG
CGACGCAGCGCCCGCC
CGCGCTCATGGCCGC
GATGACGACCAGCCC
GCGACGTCGCCGTGTCG
GGCGTCGACTTCGGC
GTATGAGGTCGGACG
CGGCCCGCTGTCCGG
CCCGCCGGCCTGCACG

-103
411
1155
162
838
620
286
461
679
-45
209
747

com
cod
com
com
com
com
com
com
cod
cod
cod
com

Bs252B

CGACCCGCCTTTCTGCACGTGG

744

com

Bs025M

CGCTTTGGCGACAACCG

65

com

Bs059A

GGATAATCATCCCGAC

169

com

Bs059B

GGATAATGGCCCCGAC

169

com

Bs211

GTTTTTTGCCGGCCTCATGG

624

com

PFK1

GGCTGCATGGTGCTCTTCATG

7

com

PFKn

ATGACCCATGAAGAGCACCA

1

cod

PFKhl

ACCTTGGGCATCTCCACC

70

com

Ml3 primer GTAAAACGACGGCCAGT

seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
seq'ng primer
make Arg-252
to Ala mutant
make Arg-252
to Lys mutant
make Arg-25
to Ala mutant
make Asp-59
to Met mutant
make Asp-59
to Ala mutant
make Arg-211
to Ala mutant
HMPFK seq'ng
primer
HMPFK seq'ng
primer
HMPFK seq'ng
primer
Univ. seq'ng
primer

Starting from first G in initiation codon in BsPFK gene,
and A in initiation codon in HMPFK gene
cod: coding; com: complementary
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Appendix 7
Denaturing Gel Electrophoresis (Smith, 1987)
1.

Assemble the BIO-RAD gel electrophoresis apparatus

using 0.75 mm X 14 cm X 14 cm glass plates.
2.

Prepare the separating gel solution by mixing 6.0 ml

of 30 % acrylamide/0 .8 % bisacrylamide, 3.75 ml of 4X
Tris-Cl/SDS (pH 8 .8 ), and 5.25 ml H20 (see reagents
below).
3.

Add 0.05 ml of 10 % ammonium persulfate and 0.01 ml

TEMED
4.

Degas in a 25-ml sidearm flask for 10-15 min.

and gently swirl to mix.

Transfer immediately the separating gel solution to

the center of the sandwich glass plates along an edge of
one of the spacers until the height of the solution about
11

5.

cm.
Using a Pasteur pipet, slowly cover the top of the gel

with 1 cm thick of isobutyl alcohol.
6.

After 1 hr at room temperature pour off completely the

layer of isobutyl alcohol.
7.

Prepare the stacking gel solution by adding 0.65 ml of

30 % acrylamide/0.8 % bisacrylamide, 1.25 ml of 4X TrisCl/SDS

(pH 6 .8 ) and 3.05 ml H20 to a 25-ml sidearm flask.

Degas for 5-10 min.
and 5 ul TEMED
8.

Add 25 ul of 10 % ammonium persulfate

and gently swirl to mix.

Pour the stacking gel solution on top of the

polymerized separating gel.
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9.

Insert a Teflon comb into the layer of stacking gel

solution without trapping air bubbles in the tooth edges
of the comb.
10. Allow to polymerize at room temperature for 1 hr„
11. Dilute an aliquot of the protein to be analyzed at
least 1:2 (vol/vol) with 2X SDS/sample buffer and boil for
5 min at 100°C.
12. Carefully remove the Teflon comb and fill the wells
with IX SDS/electrophoresis buffer.
13. Pour 2 liters of IX SDS/electrophoresis buffer into
the lower buffer chamber and place the gel in the
electrophoresis apparatus.
14. Fill partially the upper buffer chamber with 300 ml of
IX SDS/electrophoresis buffer so that the sample wells of
the stacking gel are filled with buffer.
15. Load the samples and carefully fill the remainder of
the upper chamber with an additional IX
SDS/electrophoresis buffer.
16. Connect the power supply to the cell and run at 10 mA
at constant current until the tracking dye enters the
separating gel then increase the current to 15 mA.
17. After the bromophenol blue dye has reached the bottom
of the separating gel, disconnect the power supply.
18. Fix the gel in 25 % methanol/10 % acetic acid for 30
m in.
19. Stain with Coomassie Brilliant Blue for at least 2
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hrs.
20. Destain with 10 % methanol/10 % acetic acid.

Reagents:
30 % acrylamide/0 .8 % bisacrylamide
acrylamide

30 g

N',N-methylene-bisacrylamide

0.8 g

H 20 to 100 ml
Filter through a 0.45 urn membrane and store at
4°C in brown bottle.
4X Tris-Cl/SDS, pH 6.8

(0.5 M Tris-Cl, 0.4% SDS)

Tris base

6.05

g

SDS

0.4

g

H20

50

ml

Adjust to

pH 6.8 with

1N

to 100 mltotal volume.

HC1 and addmore H20
Filter

through 0.45 urn

membrane and store at 4°C.
4X Tris-Cl/SDS, pH 8.8

(1.5 M Tris-Cl, 0.4% SDS)

Tris base

91 g

SDS

2g

H20

400 ml

Adjust to pH 8.8 with 1 N HC1.
ml total volume.

Add H20 to 500

Filter the solution through

a 0.45 urn membrane and store at 4°C.
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2X SDS/sample buffer
To 40 ml water add:
Tris base

1 . 52 g

glycerol

20

ml

SDS

2

g

2 -mercaptoethanol

2

ml

Bromophenol Blue

1

mg

Adjust to pH
100

6.8

ml with

membrane

and complete the ■
H 20. Filter through 0.45 urn

and store at 4°C.

5X SDS/Electrophoresis buffer
Tris base

15.1 g

glycine

72.0 g

SDS

5.0 g

H20 to 1000 ml
Staining solution
Coomassie Brilliant Blue R-250
Acetic acid

2.5 g
42 ml

Methanol

454 ml

H20

454 ml

Mix for 1 hr and filter.
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